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 ABSTRACT 
 
Early detection of cancer plays a crucial role in determining disease prognosis. The major 
challenge consists in the ability of identifying the disease through the quantification of a set of 
specific biomarkers in tissues and/or, more interestingly, released in the bloodstream. Non-
invasiveness, sensitivity, parallelization, low cost, are some of the most relevant keywords in 
this field. Hence the development of miniaturized devices for the early detection of cancer is 
at the core of nanodiagnostics, requiring the recognition and quantification of low amounts 
of specific disease biomarkers, through the development of sensitive diagnostic tools. In this 
context, we have developed a nanodiagnostic platform for the non-invasive quantification of 
cancer biomarkers circulating in the bloodstream. The assay, that relies on Atomic Force 
Microscopy (AFM), is based on molecular manipulation to create density-optimized 
functional spots of surface-immobilized binders and differential AFM topography. It is label-
free, allows the parallel detection of different cancer biomarkers, entails a single binder per 
antigen and when implemented with fluorescence labelling/readout can be used for epitope 
mapping. The possibility to exploit DNA nanografting and subsequent immobilization of 
binders through DNA-directed immobilization confers robustness to the assay. We explored 
the feasibility of novel binders as camelid nanobodies and aptamers, to improve the quality of 
the functionalization, and therefore device sensitivity, with the added advantage of binders 
easy engineering. In this study we focused on a prospective, clinically-relevant circulating 
cancer biomarker, the extra-cellular domain (ECD) of Human Epidermal Growth Factor 
Receptor (Her2), whose shedding and release in the blood is related to the progression of 
Her2-positive tumors and response to anticancer therapies. By employing robust, easily 
engineered camelid nanobodies as binders, we measured ECD-Her2 concentrations in the 
range of the actual clinical cutoff value for Her2-positive breast cancer. The specificity for 
Her2 detection was preserved when measured in complex matrices as standardized human 
serum, and in parallel with other potential biomarkers, demonstrating the intended 
implementation of multiplexing analysis, strongly required to define the biological tumor 
subtype and to univocally refer specific molecular levels to tumor status and progression. 
A better understanding of the Her2 receptor biology, overexpression in tumor cell 
membranes and release of the ECD to the bloodstream is however required to interpret the 
measured levels of ECD-Her2 at best. At present, there are controversial studies and 
conflicting results about the correlation between the protein levels in serum and the attested 
Her2 status in tumor tissue, which make the clinical significance of circulating ECD-Her2 still 
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uncertain. Therefore we developed a multi-integrated approach in order to elucidate Her2 
overexpression, dimerization and ECD shedding mechanism and to fully validate its 
prognostic value; moreover we preliminarily studied some fundamental aspects of the 
relationship between rafts-mediated exosomes formation and Her2 integration on them in 
order to clarify its possible role in metastasis occurrence. This approach relies on different 
multi-scale techniques and enables to correlate information coming from advanced optical 
microscopies (membrane proteins localization), nanotechnology-based diagnostic tools 
(detection of protein and vesicle biomarkers) and novel super resolution fluorescence 
microscopies (quantification and co-localization of different biomarkers). This innovative 
platform will be instrumental in identifying and quantifying clinically useful biomarkers and to 
translate basic science results into the clinics to impact cancer diagnosis, prognosis, and 
therapy. 
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 INTRODUCTION 
 
1. BREAST CANCER 
Breast cancer is the most common cancer in women worldwide, accounting for nearly one in 
three cancers diagnosed among women in the United States, and the second leading cause of 
cancer death around the world [1,2]. 
It is the most frequently diagnosed tumor type in 140 out of 184 countries worldwide [2]. 
Breast cancer is not a single disease but it is an ensemble of many biologically different 
diseases that are characterized by different genetic variations, gene expression profiles 
pathological features and clinical implications [3,4].  
Despite advances in cancer treatment, many patients still fail therapy, mainly because of 
intrinsic inter-tumoral and intra-tumoral heterogeneity, facing disease progression, recurrence, 
and reduced overall survival [5]. 
 
1.1 CLASSIFICATION OF BREAST CANCER SUBTYPES 
Breast cancer refers to several types of neoplasm arising from breast tissue, the most 
common being adenocarcinoma of the cells lining the terminal duct lobular unit. The cancer 
cells are similar in phenotype to the normal basal or luminal cells, the two distinct types of 
epithelial cell found in the ductal structure [6] (Fig. 1). 
 
Fig. 1 Breast cancer pathogenesis and cross-section view of mammary terminal duct lobular unit; 
breast cancer pathogenesis and histologic subtypes. Adapted from McMaster Pathophysiology Review - 
http://www.pathophys.org/breast-cancer/ 
 
Due to the intrinsic heterogeneity of breast cancer a classification system has been developed; 
this classification has been improved and modified over many decades, following the 
progresses obtained in cancer research [7]. The traditional histological and anatomo-
pathological evaluation has been superseded by the precise molecular characterization carried 
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out by gene profile analysis [7,8]. This approach allows a new paradigm of breast cancer 
patients stratification which provides an increased accuracy of disease prognosis and 
therapeutic strategy [8].  
The pioneer studies conducted by Sørlie et al. identified five intrinsic, distinct subtypes: 
luminal A, luminal B, Her2-enriched, basal and normal-like breast tumors [9]. 
Except for normal-like tumors which are characterized by a normal breast tissue profiling 
[10], each of the five subtypes is accurately described by a molecular profile, 
immunoistochemical and clinic-pathological features; the main criteria of the characterization 
is the presence/overexpression of specific protein receptors. A portrait of these four 
subfamilies is summarized in Fig. 2.  
 
Fig. 2 Breast cancer molecular subtypes. Adapted from McMaster Pathophysiology Review - 
http://www.pathophys.org/breast-cancer/ 
 
Luminal cancer 
Luminal tumors are the most common subtypes among breast cancer, with luminal A being 
the majority (50% of breast cancer patients). The luminal-like tumors express the hormone 
receptors Estrogen Receptor (ER) and/or Progesterone Receptor (PR) [10]. It is possible to 
distinguish two subtypes of luminal-like tumors, luminal A and luminal B. They represents 
the ER+, PR+, Her2- (ER or PR positivity and Her2 negativity) and ER+, PR+, Her2+ (ER 
or PR positivity and Her2 positivity) subtype, respectively [10]. Luminal A tumors have 
higher expression of ER-related genes and lower expression of proliferative genes than 
luminal B cancers [9]. Luminal B tumors tend to be of higher grade than luminal A tumors.  
The luminal subtypes carry a good prognosis, and luminal B tumors have a significantly worse 
prognosis than the luminal A subtype. Luminal tumors respond well to hormone therapy but 
poorly to conventional chemotherapy, although luminal B tumors which are more 
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proliferative may benefit more from a combined chemotherapy and hormonal treatment 
strategy [8].  
 
Her2-enriched cancer 
The Her2 overexpression tumors, which represents al least 15-20% of all breast cancers, 
exhibit abnormal high quantities of Human Epidermal Growth Factor Receptor 2 
(Her2): a Her2-positive cancer cell has approximately 2 million Her2 proteins on its surface, 
around 100 times more than a normal cell [11]. Her2-positive tumor tends to be more 
aggressive, to spread more quickly and to have worse survival outcome than other types of 
breast cancers [8,9]. Their poor prognosis derives from a higher risk of early relapse and 
metastasis occurrence and relative resistance to hormonal agents [8]. The use of molecularly 
targeted agents such as the monoclonal antibodies Trastuzumab and Pertuzumab is at 
present the preferential strategy for Her2-positive cancer treatment. 
 
Basal-like cancer 
The basal subtype represents 10-20% of all breast carcinomas and is also named “triple 
negative” due to the expression profile ER-, PR-, Her2- [8], lacking or low expression of 
hormone receptors and Her2, and high expression of basal markers (cytokeratins CK5/6, 
CK14, and CK17) [10,12]. These tumors are of particular aggressiveness and currently lack 
any form of standard targeted systemic therapy, leaving chemotherapy be the only clinical 
approach. They are associated with a lower disease-specific survival and a higher risk of local 
and regional relapse [8]. Metaplastic breast cancer is a type of triple negative breast cancer 
that grows and spreads more quickly: it describes a cancer that begins in one type of cell, such 
as glandular epithelial cells, and changes into another type of cell, such as nonglandular cells 
[13].  Triple negative breast cancer often associated to the presence of mutations in two 
genes called BRCA1 and BRCA2. The genes code for a DNA repair pathway that is 
important for protecting against mutations. The loss of either gene confers a high risk of 
breast cancer, as well as other cancers. Hence this kind of breast cancer is hereditary, meaning 
that there is a known genetic mutation causing increased cancer risk in the patient’s family 
[14].  
The “ER- and PR-” signature of Her2-positive and triple negative subtypes make the 
diagnosis and prognosis of such kinds of tumor critical. Since at present 
immunohistochemistry (ICH) is the key methodology to define them, standard techniques 
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employed in pathology laboratories are essential for identifying these subtypes to avoid false 
positive and negative results and hence to improve the efficacy of diagnosis. 
1.2 BREAST CANCER SCREENING: DRAWBACKS OF STANDARD 
MOLECULAR TESTS AND THE INCREASING IMPORTANCE OF 
“LIQUID BIOPSY” 
The landscape of breast cancer diagnosis and treatment is commonly investigated by means 
of molecular techniques used in current clinical practice. Immunohistochemistry is the 
primary routine detection tool: by means of stained monoclonal or polyclonal Abs it allows to 
detect specific receptor overexpression in tissue sections [15,16]. In combination with this 
standard technique there are other two US Food and Drug Administration (FDA)–approved 
assays used for the molecular profile of breast cancer, in situ hybridization (ISH) and 
fluorescence in situ hybridization (FISH) that are capable to detect gene amplification of 
the target. Furthermore, the Next Generation Sequencing (NGS) approach recently 
allowed to obtain ‘‘gene panel testing’’, covering a large number of screened genes on a single 
platform [15,16]. 
All these diagnostic tests, from the simple IHC to the more complex FISH and NSG, have 
different levels of experimental procedure complexity and cost, but the common requirement 
of a tissue sample as starting test material, obtained through surgical tissue biopsy. This aspect 
is becoming a huge limitation in terms of efficacy of clinical outcome: tumor tissue is not 
always available for molecular analysis, since some human body regions involved in the 
metastatic disease could have a poor accessibility and due to the fact that the surgical tissue 
resection of multi-metastasis could be strongly invasive. Moreover intra-tumor heterogeneity 
and the capability of cancer genome to evolve with time, particularly as resistance develops in 
response to treatment [17], make the tissue biopsy an unsuitable tool for a relevant and 
significant molecular profiling. Thus, to fully enable personalized medicine it is important to 
have an easily accessible, minimally invasive procedure to recognize and follow the molecular 
markers of a patient’s tumor. One viable route is the liquid biopsy, by which the 
genetic/proteic portrait of the tumor can be assessed through specific biomarkers released in 
biofluid samples. Liquid biopsies have the potential to monitor early primary or recurrent 
disease and to evaluate the response to treatment and to estimate risk and mortality [17,18]. 
 
1.3 BREAST CANCER CIRCULATING BIOMARKERS: “NEW GENERATION” 
BIOMARKERS 
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Both healthy and diseased cells transmit information on their state to the bloodstream, either 
through the release of biomolecules or as cell signalling intermediates (microvesicles, 
metabolites). In principle, all of them can be exploited as suitable “new generation” 
biomarkers for the liquid biopsy. The most common are:  
- circulating cell-free DNA (cfDNA). Elevated levels of cfDNA, derived partially from 
reduced DNase activity, are seen in breast cancer, but sometimes also in some benign breast 
disease; therefore, levels of cfDNA are not tumor-specific markers. However, it is possible to 
distinguish between patients with breast cancer and healthy female controls by comparing 
cfDNA profiles and studying specific patterns of cfDNA modification (i.e. mutations, loss of 
heterozygosity (LOH) and hypermethylation) [17,19];  
- circulating microRNAs (miRNA). miRNAs, as regulators of gene expression can 
modulate the expression of the protein-coding genes and hence they are involved in the 
regulation of many cellular functions in several diseases. miRNA profiles can classify human 
cancers, including breast cancers and potentially determine the tissue of origin for cancers of 
unknown primary origin [17]; 
- circulating tumor cells (CTCs). Tumor cells capable to disseminate from the primary 
tumor to distant organs through the peripheral bloodstream are named CTCs. Many studies 
have shown that CTCs are of prognostic significance in various metastatic carcinomas 
including breast cancer and are associated with decreased progression-free survival. CTCs are 
also potential source of both cfDNA and miRNA [17,20]; 
- exosomes. They are small extracellular vesicles (EVs) ensuring transport of molecules 
between cells and throughout the body. EVs contain specific signatures (RNA, DNA and 
protein) and, functioning as inter-cellular messengers, have been shown to strongly impact on 
the fate of recipient cells [21,22]. Exosomes have been proposed to play an important pro-
tumorigenic role, stimulating tumor cells growth, suppressing the immune response and even 
being part of the cancer progression and the metastatic process. It has been shown that breast 
cancer cells secrete exosomes with specific protein signatures, as crucial factor for metastasis 
occurrence [23]. In particular, among the different subtypes of breast cancer, Her2-enriched 
tumor spreading seems to be highly regulated by huge secretion of Her2-containing exosomes 
[24]. 
Moreover, together with all the mentioned above innovative biomarkers, Her2-positive breast 
cancer exhibits another category of biomolecule that is released into the bloodstream: the 
protein extracellular domain (ECD) of the transmembrane receptor Her2. Therefore, 
although the precise correlation between Her2 tissue status and ECD-Her2 serum level is still 
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debated and deeply investigated, Her2 testing in liquid biopsy is becoming complementary in 
a more and more relevant way to IHC/FISH tests, aiding in identifying Her2-positive patients 
[25]. 
 
Fig. 3 Blood circulating cancer biomarkers. Adapted from "Liquid biopsy in the clinic” 
http://www.nature.com/nrclinonc/posters/ liquidbiopsies/index.html 
 
 
2. HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 
(Her2) 
The human Her2/neu proto-gene, mapped to chromosome 17q21, encodes for a Her2 
receptor that has a structure consistent with a growth factor receptor. Her2 is a 1255 amino 
acid, 185 kDa transmembrane glycoprotein receptor that belongs to the Her family, which 
also includes Her1, Her3 and Her4. It plays a key role in the Her family, cooperating with 
other Her receptors through a complex signaling network [26,27,28].  
Normal tissues have a low amount of Her2 membrane protein. Her2 gene amplification 
causes the overexpression of the receptor and the alteration of its normal control of cell 
mechanisms, leading to malignancy and tumor occurrence [27,28]. Her2 
overexpression/amplification has been observed in 20% to 30% of breast cancer and it is 
associated with a worse biological behavior and poor prognosis [28], reduced overall survival 
and time to relapse [29].  
Breast cancers can exhibit up to 25–50 copies of the Her2 gene, and up to 40–100 fold 
increase in Her2 protein resulting in 2 million receptors expressed at the tumor cell surface 
[29]. This status is maintained during progression to invasive disease and to metastasis onset. 
 
2.1 BIOLOGICAL ROLE AND SIGNAL TRASDUCTION PATHWAYS 
Her2 plays an important role in human development (nervous system, developing bone, 
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muscle, skin, heart, lungs and intestinal epithelium). It is involved in many biological 
processes related to normal breast growth and development, such as myelination, regulation 
of cell adhesion, signal transduction, regulation of transcription, differentiation and survival 
[27].  
Her2 has the strongest catalytic kinase activity among family members; as other tyrosine 
kinase receptors, Her2 proteins undergo dimerization and transphosphorylation of their 
intracellular domains and then activate multiple downstream pro-proliferation signalling 
pathways. Considering the Her2 multiple interactions with the different members of the 
receptor family, Her2 signalling is a very complex network with a variety of pathways. The 
two main transduction routes are the mitogenic Ras/Raf/ Mitogen-activated protein kinase 
(MAPK) cascade that promotes positive regulation of cell growth and proliferation, and the 
pro-survival Phosphoinositide 3-kinase (PI3K)/Akt cascade that inhibit apoptosis processes. 
 
Fig. 4 The Her2 pathway promotes cell growth and division when it is functioning normally: the 
binding of EGF to Her is required to activate the MAP Kinase pathway as well as the PI3 
Kinase/AKT pathway, which in turn activates the NF-κB pathway. Signaling compounds called 
mitogens (specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular 
domain of the Her family of receptors. Those bound proteins then dimerize, activating the receptor. 
Her2 sends a signal from its intracellular domain, activating several different biochemical pathways. 
These include the PI3K/Akt pathway and the MAPK pathway. Signals on these pathways promote 
cell proliferation and the growth of blood vessels to nourish the tumor (angiogenesis). 
 
2.2 STRUCTURE AND MECHANISM OF ACTIVATION 
As the other members of the family, Her2 is composed by three main regions: the 
extracellular domain, with two leucine-rich domains responsible for ligand binding, and two 
cysteine-rich domains with disulfide bond connectivities, responsible for receptor 
dimerization; the lipophilic transmembrane segment; the amino- and carboxyl-terminal lobes 
of the kinase domain and the carboxyl-terminal tail [27,30]. 
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Fig. 5 Structure of the Her2 receptor 
 
The Her receptors exist as monomers on the cell surface and after ligands binding to their 
extracellular domains, they undergo dimerization and transphosphorylation of their 
intracellular domains, initiating a variety of signaling pathways. Unlike other Her receptors, 
Her2 has no known direct activating ligand; it may constitutively be in an activated state or 
can heterodimerize with other family members such as Her1 and Her3 [29]. Due to a strong 
interaction between the two leucin-rich domains, Her2 always adopts a conformation which 
is similar to that of ligand-bound receptors, in which the dimerization arms remain 
constitutively extended and free to homo- or heterodimerize [30]. Her2 heterodimers are 
more potent than the corresponding homodimers, due to a particularly high-affinity and 
slow-rate dissociation ligand binding: overexpression of Her2 promotes an abundant 
heterodimerization, enhancing the preferential binding of ligands to Her2 low-affinity arm. 
This process is crucial in the oncogenic model [27]. The most active signaling complex is 
formed between the kinase-deficient receptor Her3 and the ligand-less receptor Her2. 
Due to the fact that Her2-Her3 combination is the most potent stimulator of downstream 
pathways and has the greatest mitogenic potential, it’s considered the most relevant Her 
heterodimers in tumor growth [29]: the unregulated co-expression of these two receptors in 
cells significantly increases their transforming activity promoting human cancer occurrence. 
 
Fig. 6 The Her receptors can form homodimers or heterodimers according to ligand 
availability. (A) EGF, TGF-, HB-EGF, amphiregulin (AR) and betacellulin bind to the 
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EGFR leading to its homodimerization. In presence of Her2, EGF drives the formation of 
EGFR/Her2 dimer, betacellulin and HB-EGF bind to Her4 leading the formation of 
homodimers. In presence of Her2, betacellulin triggers the activation of Her2/Her4 
heterodimers. The four NRG ligands (NRG1-4) bind to Her3 and to Her4. NRG4 and HB-
EGF bind to Her4 dimers only. NRG1-3, betacellulin and, to a lesser extent, epiregulin drive 
the heterodimerization of Her2 with Her3 and Her4. Adapted from doi: 10.3978/j.issn.2224-
4778.2015.06.01 
 
2.3 EXRACELLULAR DOMAIN (ECD)-Her2: ROLE AND PROGNOSTIC 
SIGNIFICANCE 
The Her2 dimer formation determines the proteolytic cleavage (shedding) of  its extracellular 
domain (ECD), a soluble fragment of  approximately 105–110 kDa, which can diffuse 
through tissue and enter the circulation [30,31,32,33]. The ECD is organized in four regions: 
two leucine-rich domains (I/L1, III/L2), responsible for ligand binding, and two cysteine-rich 
domains (II/CR1, IV/CR2) connected by disulfide bonds and involved in receptor 
dimerization [30]. 
The Her2 cleavage position has been located in the juxtamembrane region: the primary 
cleavage site has been located at amino acid position 647–648 and a minor cleavage site has 
been located at amino acid position 644–645 [33]. Her2 shedding has been associated with 
cleavage by matrix metalloproteinases (MMPs) and in particularly ADAM disintegrins. 
Proteolytic release of  ECD-Her2 results in two effects: it acts as ligand, modifying the activity 
of other unrelated receptors; most importantly, creates a constitutively active N-terminally 
truncated receptor (p95Her2) which increases Her2 tyrosine kinase activity, delivering growth 
and survival signals to cancer cells and rising the oncogenic potential [30]. 
Many studies have measured the concentration level of serum ECD-Her2 in breast cancer 
patients, finding an increased level of the shedded portion of the receptor that is also 
correlated with the presence of Her2 overexpression in tumor tissue [34]. Elevated amount of 
ECD-Her2 has been detected in 30% to 70% of patients with metastatic breast cancer 
(MBC); moreover rising serum Her2 concentrations have been associated with progressive 
metastatic disease and a poor response to chemotherapy [35]. 
The most used cutoff value of circulating ECD-Her2 is the one established from the 
Immune One – Bayer ELISA kit (as better explained in the paragraph 2.5) and corresponds 
to 15 ng/mL. According to this test, healthy individuals typically exhibit ECD-Her2 levels of 
2 to 15 ng/ml while breast cancer patients levels as high as 15 to 75 ng/ml [34,36]. Therefore 
these studies demonstrated that the released ECD-Her2 might be used as a useful biomarker 
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and that diagnostic tools measuring ECD-Her2 levels in serum may provide useful 
information for monitoring early disease relapse, cancer progression or response to therapy 
[37]. 
 
2.4 Her2-TARGETED THERAPY IN CLINIC 
Since Her2 is often amplified/overexpressed in cancer cells, it has been regarded as a tumor-
specific target in molecular therapies. The main therapeutic approaches to target Her2-
positive cancer rely on two different strategies: inhibition of Her2 dimerization and inhibition 
of Her2 protein tyrosine kinase activity. 
The first approach is based on the use of Humanized Monoclonal Antibodies (MAbs) 
directed against the extracellular domain of Her2 that, once bound, block the dimerization of 
the receptor and hence the downstream signaling pathways. Nowadays two Mabs have been 
approved by FDA for their clinical use in Her2-positive cancer treatment: 
- Trastuzumab (Herceptin), that binds to domain IV of the extracellular segment of the Her2 
receptor. Although the mechanisms by which it exerts its antitumor effect are not yet 
completely understood, the most likely hypothesis is that, after binding the ECD, it blocks 
not only the dimerization but also the ECD cleavage and so prevents the production of an 
active truncated Her2 fragment that is associated to a more aggressive behavior in breast 
cancer [38]. Some evidences demonstrated that Trastuzumab seems to have its greatest 
effects in tumors with increased number of Her2 homodimers [39] and that elevated ECD-
Her2 has a biological relevance in the susceptibility to Trastuzumab-based therapy. On the 
other hand patients treated with Trastuzumab show a decrease in concentrations of serum 
ECD-Her2 [48] and individuals who did not achieve a significant decline (>20%) in serum 
Her2 levels have decreased benefit from Trastuzumab-based therapy [40]. 
The approval of this agent was based on evidence of a significant prolongation in disease-free 
survival in women receiving Trastuzumab and chemotherapy compared to those receiving 
chemotherapy alone [29]. 
- Pertuzumab, that binds Her2 near the junction of domain I, II and III and blocks the 
activation of the Her2 receptor by hindering dimerization and association with its partner 
receptors. Pertuzumab elicits action at a different ligand binding site from Trastuzumab; 
Pertuzumab binding mediates the same antibody-dependent cytotoxic effects as Trastuzumab 
binding, although it does not block Her2 shedding as Trastuzumab does [41]. 
Also Pertuzumab has completed clinical trials in combination with Trastuzumab and 
chemotherapy on metastatic breast cancer [29]. 
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The second approach is based on the use of small molecule drugs that inhibit the tyrosine 
kinase activity of the intracellular domain of Her2 (ICD-Her2) interrupting signaling 
molecular cascades. Lapatinib is the most used inhibitor in patients whose tumors are 
Trastuzumab-resistant; when combined with some chemotherapy drugs in patients with 
metastatic disease, it increases the patient benefit [29]. 
 
2.5 Her2 DETECTION IN BREAST TUMOR: STATE OF ART AND PITFALLS 
An accurate determination of Her2 status is of crucial importance in disease diagnosis, 
guiding therapy and increasing drug responses. 
The FDA has approved some of Her2 diagnostic tests. Currently, the most commonly used 
Her2 diagnostic tests include both tissue-based methods (IHC and ISH) and serum-based 
methods (ELISA) [35,36]. 
At present, the tissue-based Her2 tests are the most frequently used initial tests to detect the 
Her2 status: according to the most recent guidelines published by the American Society of 
Clinical Oncology only patients with a uniform intense membrane staining of more than 30% 
of invasive tumor cells on IHC, and a Her2/neu-to-chromosome 17 centromere (CEP17) 
ratio of greater than 2.2 on FISH are considered Her2-positive and are eligible for 
Trastuzumab treatment [42]. ICH and FISH are highly accurate but, as discussed before, 
suffer from the limitations of the impracticality and invasive nature of continuously taking 
biopsies for disease-monitoring purposes. 
Moreover variation in the procedures adopted by different labs to assess in the distribution of 
Her2 in tumor tissues determines inconsistent reporting of IHC or FISH; in many cases there 
is also a significant discordance between the IHC and the FISH results. The inherent 
heterogeneity complicates the scenario: tumor cells are prone to switch their clinical Her2 
status as a result of growing of subclones overlooked in primary tumors under selective 
pressure. This could determine discordance in a meta-analysis addressing Her2 status assessed 
by IHC and FISH on tumor tissues from primary tumors and corresponding relapse. 
In the recent years all these concerns about whether IHC and FISH suffice for Her2 testing 
raise the interest towards the serum Her2 immunoassay (ELISA) as potential dynamic, real-
time and non-invasive test to measure soluble Her2 quantitatively and to supplement existing 
Her2 testing [34,35]. It is important to underline that currently the serum Her2 assay is not 
used for screening purposes and is not a substitute for tissue testing, but is intended for the 
follow-up and monitoring of patients with metastatic breast cancer whose initial serum Her2 
value is above 15 ng/ml [43].  
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Although the great potentiality and utility the serum immunoassay has some issues mainly 
related to the experimental procedure: serum interference might cause unexpected elevated 
levels of protein and hence a false positive result. Due to the kinetic nature of serum ECD-
Her2 levels, it is highly possible that a patient could have both abnormal and normal serum 
ECD-Her2 levels depending on the time of serum collection. 
The antibodies used in the immunoassay are another important aspect to be evaluated for the 
significance of the test: some antibodies show incompatibility if the serum samples are from 
patients who are treated with Trastuzumab, due to their competitive binding with the target 
[40]. In addition false results can be caused by the heterophilic human anti-animal 
immunoglobulin antibodies (HAIA), especially the human anti-mouse antibodies (HAMA), 
that bind to animal antibodies by cross reactivity [44,45]. These antibodies are easily acquired 
through blood transfusions, vaccinations, treatment with mouse monoclonal antibodies, or 
from handling animals and are known to bind to mouse antibodies commonly used in serum 
cancer biomarker tests, including serum ECD-Her2 [34], reducing the significance of the 
measurement and pushing for enhanced selectivity in serum immune-test. 
But the crucial point that has to be investigated to definitely endorse the clinical relevance of 
ECD-Her2 and hence to validate circulating ECD-Her2 serum assays is the correlation 
between the protein level in serum and the attested Her2 status in tumor tissue. 
 
2.6 CHALLENGES IN CLINICAL UTILITY OF ECD-Her2: CORRELATION OF 
TUMOR TISSUE Her2 STATUS AND SERUM ECD-Her2 
 
Many recent in vitro studies have evaluated the correlation between abnormal ECD-Her2 in 
serum and Her2 positivity in tissue, generating conflicting results [30,46]: some have shown 
that the protein level (detected with quantitative immunofluorescence in patients tissue 
microarrays) is high even in the absence of gene amplification; on the contrary some others 
have demonstrated that when Her2 gene amplification occurs, the high protein expression 
level might decrease the cells ability to cleave or process the Her2 protein, decreasing the 
amount of released ECD-Her2 [46]; other studies have shown that Her2-negative primary 
tumors may have Her2-positive paired distant metastases or that Her2 overexpression may be 
lost during metastatic progression.  
The discrepancy between serum ECD-Her2 levels and tissue status might become an obstacle 
for the clinical utility of the baseline ECD-Her2. Possible explanations accounting for this 
discrepancy are discussed below. 
Alternative splice variants of Her2 exist, including the two soluble forms of Her2, also known 
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as p100 and Herstatin. p100 is composed of the first 633 amino acids and contains the ECD 
subdomains I–IV then Herstatin includes the first 340 amino acids of Her2 with two ECD 
subdomains (I and II) and ends with a unique carboxyl tail sequence by which it binds to 
ECD-Her2 subdomain II similarly to Pertuzumab, interfering with Her2 dimerization. The 
products of this alternative splicing can escape into the circulation because they are soluble 
[30]. Whereas the full length p185 Her2 is associated with pro-oncogenic receptor activity, the 
two soluble forms of Her2 (p100 and Herstatin) may have an anti-oncogenic function by 
inhibiting receptor dimerization and tumor cell proliferation. The current FDA-approved 
serum Her2 immunoassay seems to not distinguish between these different variants possibly 
altering the correlation between serum ECD-Her2 and tissue Her2 [33]. In this direction the 
discovery of binders that recognize “neoepitope” on ECD-Her2 could help to discriminate 
these variants [33]. 
The high concordance in Her2 status and serum ECD level may be affected also by the lack 
of ECD-Her2 expression, as one of the mechanisms of resistance to Trastuzumab therapy 
[46,47].  
In addition some studies reported discordant ICD-high/ECD-low expression that can be 
explained considering the well known mechanisms of ECD cleavage or the expression of a 
truncated Her2 protein that lacks the ECD. However these findings suggest that the ability to 
predict Her2 gene amplification is strongly affected by the different protein domain 
specificity exhibited by IHC antibodies [46]. At present, it remains unclear whether patients 
with elevated serum ECD also express correspondingly high levels of cell membrane-bound 
activated ICD-Her2 in either Her2-overexpressing primary breast cancer or MBC patients 
[48]. 
In general, few studies attempt to compare tissue and serum data, and to precisely correlate 
dimerization with ECD shedding at different level of tumor progression and in response to 
therapy. Knowing whether the level of shedded ECD-Her2 helps predicting tissue Her2 
status, would validate ECD-Her2 screening in the serum as complement determination of 
tissue testing and would help to define Her2 status with greater accuracy, both in early breast 
cancer and in metastatic disease. 
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2.7 MEMBRANE LIPID MICRODOMAINS: A CRUCIAL ROLE IN THE 
REGULATION OF Her2 ACTIVATION AND Her2-CONTAINING 
EXOSOMES RELEASE 
 
With the proof of dynamic protein distribution in the cell membrane, the fluid mosaic 
model was introduced and has become the most accepted model until now. The fluid mosaic 
model highlights that: i) both lipids and proteins are dynamic and diffuse randomly in the 
homogeneous lipid bilayer and ii) proteins are asymmetrically distributed in the cell 
membrane. In recent years however many experimental findings went in conflict with this 
classical model and indicated that cell membranes also contain various nano/micro-sized 
domains. In particular lipid rafts are membrane domains enriched in sphingolipids (i.e. 
ganglioside GM), cholesterol and GPI-anchored proteins. They are small, heterogeneous, 
highly dynamic and play an important role in membrane trafficking and signal transduction. 
In particular these microdomains cluster together with proteins involved in the regulation of 
crucial cellular processes, many of which are altered in pathological disease, as cancer 
[49,50,51]. 
Quantitative florescence microscopy studies have demonstrated that clusters of Her2 
colocalize with lipid rafts on Her2 overexpressing breast cancer cells [52,53]. Both 
gangliosides GM1 and GM3 are thought to modulate Her2 dimerization activity by retaining 
Her2 within the lipid raft, thereby modulating the local density of Her proteins and increasing 
the probability of dimerization and activation [54]. It has been observed that Her2 
dimerization in breast cancer cells takes place in a particular sub-family of rafts, called 
caveolae, that are non-clathrin invaginations of the plasma membrane enriched in the family 
of integral membrane proteins known as caveolins [49,53].  
 
Fig. 7 Lipid and protein components of (A) non-caveolar lipid rafts and (B) caveolae. Adapted from doi: 
10.5772/21324 
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From different studies, it has then been proposed that lipid rafts influence the association 
properties and the biological function of Her2 and that the dissociation of the rafts decreased 
Her2 dimerization. [49,52]. The presence of rafts and the membrane rigidity could be also 
responsible of the lateral mobility of the ADAM metalloproteases and their protein substrate, 
affecting the shedding process and the serum ECD-Her2 release [30]. Moreover, recent 
studies demonstrated how the substrate selectivity of ADAMs and consequently their 
shedding activity is strictly connected to their localization into distinct lipid rafts. For this 
reason, high levels of endogenous fatty acids should promote kinetically favorable 
interactions between Her2 and ADAM proteases in lipid rafts microdomains, enhancing Her2 
shedding [30]. 
The evidence that lipid rafts play a fundamental role in providing a microenvironment 
favoring Her2 dimerization which in turn drives tumor transformation and progression opens 
the possibility to target lipid rafts for cancer treatments and hence interfering with Her2-
driven proliferation of breast cancer cells [52]. 
The preferential Her2 localization and functional interaction in caveolae open another 
interesting scenario; caveolae are known to regulate important processes such as signal 
transduction within the cell, vesicular transport, cell migration and cell cycle, since they are 
the preferential regions for the inward budding of the plasma required for vesicles-mediated 
transport machinery. By means of caveolae-driven vesicles formation, signalling molecules 
could be compartmentalized and properly released from cells and spread in distant tissue. 
This mechanism has important implications in numerous human pathological conditions, 
such as tumorigenesis and metastatic spread. Recent experimental evidences [55] grew the 
interest on the understanding the precise role of caveolae in cancer regulation. The main 
protein component of caveolae is Caveolin-1 (Cav1), an integral membrane 21–22 kDa 
scaffolding protein that coats 50–100 nm plasma membrane invaginations. It has been 
observed that Cav1 is commonly up-regulated in several advanced epithelial tumors including 
breast carcinomas.  
Some studies demonstrated that even if an initial loss of Cav-1 is observed in breast cancer, 
re-expression of Cav-1 at later stages might correlate with more malignant characteristics [55]. 
Moreover high expression of Cav1 positively correlates with increased invasion and 
migration, and this seems to be strictly related to the overexpression of Cav1 in secreted 
tumor exosomes [56,57]. For this reason a prominent role in Her2-enhanced cancer 
progression and spreading seems to be attributed to Her2-positive exosomes. Additionally, 
Her2-positive exosomes have been shown to confer the phenotypic traits of their originating 
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cells to recipient cells [58] and are enriched in proteins involved in metabolic pathways related 
to cancer progression [59]. 
However further investigations are still necessary to understand the role of Cav1 in exosome 
biology and in particular the relationship between rafts-mediated nano-vesicles formation and 
transport (transcytosis, endocytosis) and Her2 integration on them. Highlighting the 
molecular mechanisms through which Her2 receptor is segregated and processed in the 
exosomes would be instrumental to understand the significance of Her2-exosome recognition 
for a complete and comprehensive Her2-status evaluation. 
 
3. NANOTECHNOLOGY IN CANCER MEDICINE 
3.1 NANOTECHNOLOGY-BASED DIAGNOSTICS: STATE OF THE ART 
The last decade has witnessed how nanotechnology, or the engineering and controlling matter 
at the molecular scale, has been able to create structures/devices with novel chemical, 
physical and biological properties. Nanomedicine in particular bears the potential to radically 
change the way to make diagnosis and treat diseases. Cancer nanotechnology is a novel 
interdisciplinary area of comprehensive research that combines the basic sciences, which 
includes biology, physics and chemistry, with engineering and medicine, with a broad 
spectrum of applications in cancer treatment, spanning from therapeutics, diagnostics and 
prognostics [60]. Noteworthy recent improvements in cancer research have expanded our 
understanding of cancer as a disease at the genetic, molecular, and cellular levels, opening 
venues for research for the development of newer approaches and technologies.  
The power of nanotechnology in cancer treatment is expected to be manifold: concerning the 
diagnostic field, nanotechnology is expected to encompass current limitations as insufficient 
sensitivity and specificity in detecting tumor conditions or early-stage cancer, inability to 
determine tumor stage, to perform predictive and accurate screening with low cost 
procedures [61]; concerning therapy, nanotechnologies are expected to develop new 
approaches to increase the specificity of anticancer drugs, the delivery of suitable drug 
concentrations to the target site, reducing toxicity effects, increase the ability to track and 
control site-specific therapeutic responses and adverse effects, and mitigate development of 
drug resistance [62].  
Among new nanotechnology methods in anti-cancer therapies, nanoparticles constitute at 
present the most promising and investigated tool. These particles, that range between 1 and 
100 nm in size, are developed as potential delivery systems for cancer therapies: with their 
unique structure and dimension they exhibit enhanced permeability and retention effect; 
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moreover they preferentially accumulate in tumors, resulting in higher drug concentrations at 
targeted sites. Therefore they provide an opportunity to change the pharmacokinetic outline 
of drugs, lowering toxicity for surrounding normal tissue, and enhance the therapeutic 
markers. Today, nanoparticle-based drug delivery platforms are made mainly by liposomes, 
polymeric nanoparticles and metal nanoparticles, depending on the material in which the 
payload is encapsulated [63,64]. 
On the diagnostics side, keywords are high sensitivity, non-invasivity and fast detection of 
disease-related biomolecules [1,25,27]. In this assorted framework, nanotechnologies provide 
evidence to bring major breakthroughs in terms of integration and miniaturization of the 
various bioassays [25]. Notable examples are miniaturized electrochemical and surface 
plasmon resonance (SPR)-based sensors, functional nanoparticles and protein/DNA 
nanoarrays which can offer enhanced precision and significantly faster measurements than 
what achievable with highly spread, FDA-approved technologies [38,39,41,47]. Miniaturized, 
integrated and multiplexing strategies are particularly urging when moving into the direction 
of non-invasive “liquid biopsy”, i.e. the detection of reliable biomarkers (proteins, nucleic 
acids, circulating cells) directly in the bloodstream of patients to monitor early-stage tumor 
occurrence as well as its evolution during systemic treatments. 
In spite of the readout technique (optical, mechanical and electrical) employed, all micro- and 
nano-biosensing systems rely on biological molecular recognition that ensures the high 
affinity capture of the target biomarker [65]. 
 
3.2 EMERGING SURFACE AND INTERFACE PROTEIN ANALYSIS 
TECHNIQUES 
Surface and interface protein analysis techniques are widely explored in the field of molecular 
biorecognition. The immobilization of the receptor on a solid support allows for the easy 
spatial separation of bound from unbound molecules, overcoming the difficulty to 
discriminate between them in solution and possibly the need of molecule labeling. Another 
advantage of surface immobilization, compared to solution, is the possibility to tune the 
parameters of the immobilization process, and to control the localization and the stability of 
the molecules. 
One of the most exploited miniaturized device for protein detection is the microarray. A   
protein microarray is a solid surface on which different proteins (i.e. antigens, antibodies, 
enzymes, substrates) are immobilized in discrete spatial locations, forming a high density 
protein dot matrix [66,67].  
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Protein microarrays can be classified into three types: analytical, functional and reverse phase 
protein arrays. Analytical protein microarrays are usually composed of biomolecules with 
specific binding activities, such as antibodies, to determine whether a sample contains a 
specific protein of interest or to analyze the components of complex biological samples. They 
have been used for protein expression profiling, biomarker identification, determination of 
cell surface marker, glycosylation profiles and clinical diagnosis [67]. On the other hand, 
functional protein microarrays are constructed by printing a large number of individually 
purified proteins, and are mainly used to comprehensively query biochemistry properties and 
to study protein–protein, protein–DNA, protein–RNA, protein– phospholipid and protein–
small molecule interactions [66,67]. Reverse-phase microarrays (RPPA) is a method that 
allows for the analysis of many samples obtained at different states by directly spotting cell 
lysate, specifically identifying certain proteins by means of many different probes [68]. The 
potency of this methodology relies on the multiplexing capability, that allow to detect 
simultaneously a great number of different antigens. However the immobilization on the 
surface of the proteins as recognition elements is a crucial step, due in particular to the 
damage and/or denaturation that may occur during the immobilization. 
Another, and probably most used, label-based solid-phase approach is the Enzyme-Linked 
ImmunoSorbent Assay (ELISA). This test is usually performed in a sandwich configuration: 
protein binder molecules, generally antibodies, are immobilized on a surface. The bound 
protein is detected through a second, enzyme-linked antibody. After the addition of the 
enzyme’s substrate, a reaction gives colorimetric signal used to quantify the analyte. 
Compared to other immunoassay methods, ELISA tests are considered highly sensitive and 
strongly specific. On the other side this assay has several disadvantages: large sample volumes 
are required (low-volume assay formats often requires automated and expensive equipment), 
cross-reactivity might occur with the secondary antibody, resulting in nonspecific signal, and, 
mainly, readout based on labeled- or colorimetric-molecules often determine false 
positive/negative results. 
Moreover, one of the main drawbacks of label-dependent detection is that manipulating 
structure of a probe or a specific antibody can affect their binding capability. Therefore, label-
free detection methods have also been investigated for protein microarrays. Mass 
spectrometry has been used for detecting ligands bound to individual proteins printed on 
protein microarrays, with approaches as MALDI (matrix-assisted laser desorption ionization)-
MS (mass spectrometry), SELDI (Surface-enhanced laser desorption/ionization)-TOF (time 
of flight)-MS, and MALDI-TOF-MS used for this purpose. Another powerful label-free 
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technology is Surface Plasmon resonance (SPR): it allows to analyze biomolecular 
interactions in real-time, and has been adapted to protein microarray signal detection. It is 
based on the principle that incident light can resonate with free electrons oscillations on a 
metal surface in total internal reflection, and that the resonance signals will change when 
ligands bind to (and/or dissociate from) ligands on the array surface. Binding event can thus 
be monitored and the kinetic parameters calculated in real-time. [66]. 
One advantage of this technique is that is label-free; on the contrary probe immobilization 
may cause the heterogeneity of surface binding.  
Atomic Force Microscopy (AFM) offers the possibility to control density and orientation of 
protein layers on gold surfaces for optimal biorecognition through nanolithography 
techniques, and simultaneously the measurement of binding interactions in a label-free way.  
 
3.3 ATOMIC FORCE MICROSCOPY (AFM): A NANOTECHNOLOGY TOOL 
FOR SURFACE-BASED BIOMOLECULAR RECOGNITION 
Scanning Probe Microscopy (SPM) is a family of powerful techniques that allow to investigate 
the local properties of a solid surface with high spatial resolution, reaching the nanometric 
and subnanometric scale. Two are the main types of SPM microscopes: Scanning Tunneling 
Microscopes (STMs) and Atomic Force Microscopes (AFMs) [69]. In both cases a nano-sized 
scanning probe is brought in close proximity of a surface (nanometers or fractions), till a 
specific probe-surface interaction is measured. Also, the probe is mounted on a piezoelectric 
motor, which allows a scanning over a plane parallel to the surface, measuring point by point 
the interaction with the surface. An electronic feedback system keeps the tip-sample distance 
or interaction constant during scanning. In the case of STM, the first SPM to be developed, 
the probe is a sharp metallic tip, and the measured interaction is the tunneling current flowing 
between the tip and the substrate, which then has to be conductive or semi-conductive; there 
is an exponential connection between the tip to sample distance and the current flow, that 
confers the unique atomic resolution [69]. An STM map of a surface is reflecting the 
distribution of the electronic states on the surface, and therefore the position of individual 
atoms. Unfortunately, few biological surfaces are conductive enough to be measured by STM. 
To overcome this limit, AFM has been introduced. In this case, interaction forces between 
the tip and the sample surface are measured: at atomic distances, van der Waals forces are in 
fact always in place, regardless of the conductive nature of the materials [70]. To measure 
such forces AFM employs special nanometer probes formed by an elastic cantilever with a 
sharp tip (radius of curvature between 1 and 10 nm) at the end (Fig. 8). The force applied to 
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the tip by the surface (or viceversa), results in a measurable bending of the cantilever [70,71]. 
Another advantage of AFM over STM for studying biological samples is the measuring 
environment: STM requires ultra-high vacuum or dry air conditions; AFM is usually operated 
in air or in liquid, including physiological conditions. 
 
Fig. 8 Schematic representation of an Atomic force Microscope. A laser beam is focused on top of 
the free end of a cantilever and reflected on a four elements detector, sensitive to the laser shifts 
during the scanning of the sample. 
 
The tip is typically made of silicon–oxide and has a radius of curvature of 10 nm for standard 
probes. The soft microsized cantilever has a spring constant that may vary according to the 
sample and the application (from few tens of pN/nm to few tens of nN/nm) that is function 
of the elastic constant of the material and of cantilever dimension. Measuring the cantilever 
deflection, it is possible to evaluate the tip–surface interaction force [70,71]. 
Cantilever deflection is measured by a laser beam focused on the top of the free end of the 
cantilever and reflected on a four-elements position-sensitive photodiode. Knowing the 
stiffness of the cantilever, in first approximation, the Hooke’s law gives the linearly 
relationship between the force required to deflect the cantilever and its deformation: 
F= -kz 
where F is the force, k is the stiffness of the cantilever, and z is the amount the lever is bent. 
A piezoelectric actuator moves accurately the AFM probe and the sample in the X-Y plane in 
a raster manner. The number of lines scanned in a surface unit contributes to the resolution 
of the image. A Z-actuator, composed by piezoelectric material as well, controls the vertical 
movement of the tip [70,71]. In the case of AFM, a typical surface map is the constant force 
contour of the surface, which in turn reflects the chemical/morphological properties of it. 
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3.3.1 AFM modes of operation 
The main interaction forces measured by AFM are the van der Waals forces: the 
interaction potential between two atoms, on the tip and on the sample, respectively, 
located at a distance r from each other, can be approximated by the Lennard-Jones 
potential function (Fig. 9). 
 
Fig. 9 AFM force-distance curve. From this curve, it is possible to understand the role of the 
different interactions depending on the distance between the tip and the sample. The tip, 
approaching the surface, starts to feel attractive long range forces (non-contact AFM region) until 
tip and surface electron orbitals are so close to start exerting repulsive forces (contact mode AFM 
region). Between these two regimes lies the intermittent-contact (or tapping mode) region. 
 
The AFM surface imaging capability can be explored in different modalities: depending 
on the tip-sample distance AFM operates in repulsive or attractive regime. When the tip 
starts approaching the surface, long-range, attractive van der Waals interaction 
predominates (depending on the nature of tip and sample, also electrostatic and/or 
magnetic forces can be present); when the tip is near (some Angstroms) to the surface, 
short-range repulsive forces dominate. When repulsive forces predominate (steeper part 
of the potential), AFM operates in static mode (or contact mode), in which the probe is 
maintained in constant gentle contact with the sample (low load); differently when 
attractive forces predominates AFM is operated in dynamic mode (non-contact and 
intermittent mode) with an oscillating probe [71,72]. 
 
The contact mode AFM (CM-AFM), as already said, is usually considered the static 
operation mode. As the name suggests, the tip is in constant, gentle contact with the 
surface of the sample. From the measure of the cantilever deflection, it is possible to 
calculate the force of interaction between the probe and the surface. In this mode, the 
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deflection of the cantilever is used as input to a feedback circuit that moves the scanner 
up and down in z, responding to the topography by keeping the cantilever deflection 
constant. With the cantilever deflection held constant, the total force applied to the 
sample is constant. In this mode, the topographic image is generated from the scanner’s 
z-motion recorded in each point of the sample. The scanning speed is thus limited by the 
response time of the feedback circuit [71,72]. 
In Non Contact-AFM (NC-AFM) the tip is positioned at a certain constant distance 
from the surface (within few nanometres) where attractive forces (electrostatic, magnetic, 
attractive van der Waals forces) predominate. Then the tip is made scanning at a given 
amplitude and frequency (generally closed to the cantilever resonance frequency). 
Variations in the resonance frequency, amplitude and phase of the oscillation are linked to 
the characteristics of the surface and to the tip-sample interactions. All these parameters 
are monitored in order to reconstruct the topography of the sample [71,72]. 
In the case of Intermittent Contact Mode (or Tapping Mode), the amplitude of the 
oscillation, influenced by long-range forces, controls the feedback system and the error 
signal (difference between the setpoint and the amplitude) is the input for the feedback 
system. The output, as in CM-AFM, controls the Z-actuator and the tip movement. 
Moreover, during the scanning it is possible to record the variation of the oscillation 
phase. This signal is particularly useful in the case of a heterogeneous material because 
gives information about the chemical properties of the sample. Since the tip touches 
intermittently the surface, the damage of the sample is significantly reduced. Despite the 
difficulties of operating in tapping mode in liquid environment due to the significant 
dumping of oscillation frequencies by the viscosity of the aqueous medium, this 
operational mode is widely applied in biological field for the study of living cells, lipid 
membranes and DNA molecules [71,72]. 
Besides the topography information of the sample another important parameter 
determined by the AFM imaging is the roughness. It is calculated as the root mean square 
average of height deviation taken from the mean image data plane and indicates the 
homogeneity of the sample. 
 
3.3.2 Self-Assembled Monolayers (SAMs) 
Self-assembly, in a general sense, might be defined as the spontaneous formation of 
complex hierarchical structures from pre-designed building blocks, typically involving 
multiple energy scales and multiple degrees of freedom. The molecular self-assembly 
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often proceeds through several consecutive stages and thermodynamically toward the 
state of lower entropy [73]. 
Self-Assembled Monolayers (SAMs) are organic assemblies formed by the adsorption of 
molecular constituents from solution onto the surface of solids. One of the most widely 
studied SAM is alkanethiols on gold. Gold is chosen as metal solid surface because of its 
many advantages: it is easy to obtain and is a reasonably inert metal exceptionally easy to 
pattern by a combination of lithographic tools; moreover gold binds thiols with a high 
affinity (30 kcal/mol) and stability and it does not undergo any unusual reactions with 
them. Alkanethiols (CH3(CH2)n-1SH, or Cn) are powerful molecules for this application: 
the thiol head group acts as an anchor group, quasi-covalently bound to the gold, while 
the carbon chain is referred as the ‘backbone’ which stabilizes the SAM due to van der 
Waals interactions between adjacent chains. The end group in the simplest case consists 
of a methyl-group. However, a lot of other functionalized end groups have been so far 
synthesized, with the added value of tuning the chemical properties of the SAM film for 
further applications [73].  
The most common protocol for preparing a well-orderd SAM of alkanethiols on gold is 
by immersion of a freshly prepared or clean substrate into a dilute ethanolic solution of 
thiols for 12-18 h at room temperature. Dense coverage of adsorbates are obtained 
quickly from millimolar solutions (milliseconds to minutes), but a slow reorganization 
process requires times on the order of hours to maximize the density of molecules and 
minimize the defects in the SAM. Indeed self-assembly is characterized by two distinct 
phases: a first one in which molecules initially attach to gold with the chains parallel to the 
surface. This ordered phase is called lying-down phase or stripe phase, with the chain 
parallel to the surface. In this phase, alkanethiol molecules bind to the Au substrate 
through the S head by losing the mercaptan H atom (two alkanethiol molecules need to 
react simultaneously with the Au surface, in order to release their H in the H2 form), 
turning in alkanethiolates (Fig. 10).  
 
Fig. 10 Schematic representation of the different phases of spontaneous unconstrained self-
assembly. Adapted from doi: 10.1146/annurev.physchem.58.032806.104542 
 
As the reaction proceeds, the increase in surface coverage results in the nucleation of 
 30
ordered domains of stand-up thiols, which eventually form a complete layer, as result of 
collision and lateral pressure. The molecules stand with their longitudinal axis tilted of 30° 
with respect to the surface, forming a compact layer well oriented with respect to the Au 
(111) surface, as the result of lateral van der Waals interactions between the chains and 
the S-Au chemical interaction [73,74].  
SAMs of alkanethiols are very much employed in micro and nanotechnology, to produce 
patterns of different chemical properties on a surface. The simplest strategy consists in 
the physical transfer of the molecular components of a SAM to the substrate in an 
imposed pattern. For that two main strategies have been employed: Microcontact 
Printing (μCP) and the scanning probe lithography [75]. In the μCP an elastomer, casted 
and cured from a master structure generated by “soft-lithography” methods, is inked by 
immersion with a molecular precursor of a self-assembled monolayer, and printed to a 
substrates (with planar or even non-planar topographies) to transfer molecules through 
the contact points and generate a SAM into the substrate, with the only requirement to 
hold some affinity for binding the head groups [76] (Fig. 11). 
 
 
Fig. 11 Schematic representation of the basic steps of microcontact printing is shown in figure 1 
at the right. A PDMS stamp is created curing the elastomer onto a surface which has the features 
one wants to reproduce. After curing, the stamp is peeled off the master, and can then be "inked" 
with the molecules to be stamped. Stamping is achieved by simple placing the inked stamp on a 
surface. The ink molecules transfer to the surface with the pattern of the stamp. Adapted from doi: 
10.1021/ja980770z 
 
Another method employed to generate SAM patterns on a surface is the Dip-pen nano-
lithography: it consists on a tip of an AFM “inked” into a solution of alkanethiol, and 
then used to scan, for instance, a gold surface. During scanning in air, a water meniscus 
forms, through which the molecules are released to the surface. This technique can write 
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lines of molecules as small as the tip dimension (few nm), and can be thermally activated 
[75]. 
Also DNA can self-assembly on gold surfaces, when is modified at on end with an 
alkanethiol (tipically C6). DNA SAMs on gold have been intensively studied and exploited 
for DNA-based microarray applications.  
  
The main difference between DNA and alkanethiols is that DNA is negatively charged. 
So, in order to screen the negative charge of DNA backbones, extra charges are needed: a 
saline solution (buffer) is added as a consequence. In fact positive ions of saline solution 
shield the DNA chains electrostatic repulsion and allow the SAM to form. Furthermore, 
the dimension of DNA strand with respect of alkanethiol introduces steric effects which 
define the structure of the monolayer: DNA SAM would not have the same packed 
structure on gold and it would be more disorganized [77,78].  
SAM density on the substrate increased with the increasing of the incubation time and of 
the concentration of DNA molecules in solution. Moreover the greater is the roughness 
of the substrate higher is the density of the SAM because it increases the number of 
active sites for anchoring the DNA. It has also been demonstrated that lower ionic 
strength solutions (measured as the electric field intensity generated by the ions in that 
solution) correspond to less probe adsorption (due to the electrostatic repulsion between 
DNA strands that are less screened) and, simultaneously, higher ionic strength solutions 
are associated to higher probe coverage [79]. 
3.3.3 AFM nanolithography: nanografting 
Nanografting is a lithographic AFM mediated technique, developed by Liu et al in 1997 
[74]. This method employs an AFM tip to locally exchange the molecules that belong to a 
pre-existing SAM layer in a selected area with other thiolated molecules present in 
solution, obtaining confined nanostructures of the grafted molecules surrounded by a 
SAM carpet of other molecules. The experimental procedure starts with the growth on an 
ultra-flat gold surface of a SAM of alkanethiols, typically oligo-ethylene glicole terminated. 
Fig. 12 Cartoon of DNA-SAM on gold 
surface. DNA is a thiol-modified DNA 
and it adsorbes on the surface via 
specific and nonspecific bonds. The 
former are S-Au bonds at higher energy 
than the latter N-Au bonds (that means 
a link between nitrogenous bases and 
gold surface). 
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This layer will be used as reference carpet for topographic measurement of the surface 
and, due to its biorepellent properties, will prevent the non-specific adsorption of 
molecules on the surface [80]. Scanning of the tip at high force (around 100 nN) 
determines the local displacement of the reference molecules and the replacement by 
thiolated molecules of interest dissolved at high concentration in the liquid medium, 
forming the so called Nanografting Assembled Monolayers (NAMs).  
 
Fig. 13 Schematic representation of nanografting procedure. The scanning of AFM tip at high 
force displaces the molecules of a reference SAM of thiols promoting the replacement with the 
thiolated molecules of interest dissolved in solution. Adapted from doi: 
10.1146/annurev.physchem.58.032806.104542 
 
There are many advantages that make nanografting a powerful tool in surface 
functionalization: it allows controlling the molecular packing of the nanostructure both in 
terms of conformation and molecular density. Moreover, the spatial confinement during 
the NAM formation (which is an exchange process, see Fig. 13B) enables directly the 
standing up configuration on the gold surface made free by the AFM tip. Finally, under 
identical reaction conditions, self-assembly occurs much faster in NAMs than in 
unconstrained SAM. In this way, it is possible to create nanostructures of large molecules 
and even biological molecules, as metal nanoparticles, DNA, ligands and proteins, in a 
well-oriented manner, with high control and precision. 
To compare DNA-nanopatches of different sizes and to learn about the density of DNA 
as a function of the number of times any given area is nanografted over, it has been 
introduced the line density parameter “S/A” where S is the scanned area and A is the 
actual area of the final patch. S/A = R·N/L in which R is the width of the tip at the point 
of contact with the surface, and N/L is the number of scan lines (in the slow scan 
direction) divided by the length of the patch L (in the same direction) [81]. It has been 
demonstrated that with increased S/A numbers the height of the nanopatch increases, to 
indicate that more DNA molecules are grafted into the same area (Fig. 14).  
 33
 
Fig. 14 (A) Schematic representation of the definition of the nanografted line density S/A 
parameter. (B) AFM topographic image of two single-stranded DNA (ssDNA) nanopatches 
obtained with S/A = 5 (left) and S/A = 34 (right). (C) A profile of the NAM in B (blue line). 
From doi:10.1021/nl802722k 
Moreover the S/A density parameter affects the hybridization with the complementary 
sequence. In the low S/A regime, after hybridization, the height of the DNA-
nanopatches increases significantly, due to the much higher stiffness of double-stranded 
DNA (dsDNA) with respect to ssDNA. Instead in the high S/A regime, in which the 
height of the nanopatches has already reached saturation, minimal change in height can be 
detected; compressibility measurements proved that hybridization also occurs in the high 
S/A regime, even with low efficiency due to steric hindrance reasons [81]. 
 
3.3.4 DNA-Directed Immobilization (DDI): a powerful strategy to develop 
nano-immuno protein assays 
 
Surface-bound DNA molecules have generated huge interest because of their potential 
applications in biosensing and biorecognition, resulting in the rapid development DNA 
microarray-based techniques [82,83]. Controlled nanoscale DNA patterning has been 
exploited to increase the sensitivity of DNA/RNA detection, and is at the core of next 
generation sequencing, gene expression profiling, comparative genomic hybridization, 
oligonucleotides mismatches detection, alternative splicing identification or microRNA 
(miRNA) detection [82,84]. 
Moreover, in the post-genome era, technology has been driven to develop multiplexed 
assays that allow studying large numbers of proteins and protein interactions in complex 
biological systems. Multiplexed assays are used for example for drug discovery to look at 
thousands of proteins in a sample [85]. Interestingly, for clinical and diagnostic purposes, 
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measuring the level of only few proteins along with controls is sufficient to monitor a 
specific disease. In both cases, however, specificity, sensitivity, reagent costs, and 
straightforwardness of the experimental procedure are the major criteria for selecting a 
technology and the relative protocols. 
Beside DNA hybridization studies, surface-bound ssDNA can also be exploited as a 
powerful strategy for reversible site-specific immobilization of biomolecules (such as 
proteins and antibodies) to build receptor arrays and parallel ligand-binding assays. 
Exploiting AFM-based nanolithography (nanografting) and the exceptionally high 
physicochemical stability of DNA oligomers one can create ssDNA nanoarrays on gold 
surfaces by successive attachment or spatially separated synthetic thiolated 
oligonucleotides [86,87]. These in turn can be used as a template for the attachment of 
protein binders chemically “barcoded” with the respective complementary strands [88,89]. 
One of the major advantages of DNA-driven antigen-binder immobilization with respect 
to direct immobilization of the binder itself, is in the robustness of DNA: DNA 
nanoarrays can be stored in inert atmosphere for months, without losing their 
biorecognition capability, and be transformed at the needed moment into a more delicate 
nanoarray platform for protein studies. 
This strategy for multiplexing probe immobilization is called DDI (DNA-directed 
immobilization), a technique introduced by Christof Niemeyer in 1994 [86,87]. Different 
DNA-conjugated antibodies/proteins targeting different antigens are immobilized via 
Watson-Crick base pairing on surface-tethered complementary DNA sequences. As well 
as the multiplexed capability another great advantage of DDI is that the proteins preserve 
their biological activity since they are attached to the surface through the DNA linker 
rather than being directly fixed to the surface through multiple covalent or non-covalent 
bounds which may limit their conformational freedom and might affect their functionality 
[90,91]. 
To effectively facilitate DNA-directed immobilization, biomolecules of interest need to 
be coupled with a ssDNA moiety, providing a specific recognition site for complementary 
nucleic acids, and thus a molecular handle for selective immobilization on DNA 
nanoarrays [86]. The generation of semisynthetic DNA–protein conjugates allows the 
unique structure-directing properties of DNA to be combined with an almost unlimited 
variety of protein functionality. The chemical covalent or non-covalent coupling of DNA 
oligomers with proteins can be obtained through various methods [90]. 
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3.3.5 Nanoscale protein arrays: conventional and novel binders 
Protein microarrays are a collection of capture binders fixed on a solid surface for the 
purpose of detecting antigens. These arrays are developed for the detection of proteins 
expression from cell lysates in general research and special biomarkers from serum or 
urine for diagnostic applications, allowing the identification of biomarkers or drug 
compounds. Arrays are used for protein expression profiling, screening, and to 
discriminate between normal, diseased or treated samples. More specifically the 
applications to cancer research include profiling proteins to identify candidate biomarkers, 
characterizing signaling pathways, and measurement of changes in modification or 
expression level of cancer-related proteins.  
The most common molecules used as capture agent covalently bound to the microarray 
surface consist in monoclonal antibodies, proteins produced by immune system and 
synthesized in pure form by a single clone population of cells. These antibodies, also 
generically termed immunoglobulins (Ig), can be made in large quantities and have a 
specific affinity for certain target molecules called antigens. 
Antibodies are large, roughly Y-shaped molecules having a molecular weight of 
approximately 150 kDa and consisting of paired heavy (H) and light (L) polypeptide 
chains. The two heavy chains are linked to each other by disulfide bonds and each heavy 
chain is linked to a light chain by another disulfide bond. Since the two heavy chains and 
the two light chains are identical, an antibody molecule has two identical antigen-binding 
sites and thus the ability to bind simultaneously to two identical structures. Each of the 
four chains has a variable region at its amino terminus, which contributes to the antigen-
binding site, and a constant region, which determines the isotype [92]. 
                         
The intrinsic properties that make antibodies (Abs) molecules suitable for recognition in 
microarrays are the relative high affinity for the specific antigen: the dissociation 
constant KD values span from low micromolar (10-6 M) to nanomolar (10-7 to 10-9 M) 
range. High affinity antibodies show a KD in the low nanomolar range - high 
Fig. 15 Structure of a human antibody: the 
light and heavy chains are linked together 
by means of disulfide bound. Both of 
them exhibit a constant and variable 
region. 
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picomolar (10-12 M) range. Moreover Abs are very robust molecules that can lead to high 
reproducibility and throughput in biorecognition performance. 
Although conventional monoclonal antibodies are still indispensable reagents in basic 
research and diagnostics there are some disadvantages that limit their use and their 
efficiency in microarray applications: elevated costs and long time necessary for their 
production. Furthermore their dimensions could make Abs inappropriate for some 
applications. The total number of biological receptor molecules immobilized on a given 
sensor surface area has in fact an impact on the biosensor sensitivity limit: a higher 
density of functional recognition molecules will facilitate the sensitive detection of low 
analyte concentrations. In the case of Abs, surface coverage could be limited by 
interference between adjacent receptor-analyte complexes. It becomes then clear that 
small-sized receptor molecules might be an asset to generate the highest possible ‘active’ 
probe densities. Therefore, much effort was put by researchers in finding the smallest 
fragment harbouring the intact antigen-binding capacity of antibodies [93]. 
In this context, single-domain camelid immunoglobulins, termed VHHs or 
nanobodies (Nb), have seen increasing attention in biotechnology, pharmaceutical 
applications and structure/function research. A single-domain antibody is a peptide chain 
of about 110 amino acids long, comprising one variable domain (VH) of a heavy-chain 
antibody, or of a common IgG. 
 
The great potentiality of nanobodies comes from different unique features that provide 
access to new epitopes in concave and hinge regions and stabilize them. The original 
procedure to generate nanobodies comprised as first step the animal immunization; the 
advent of naïve libraries facilitated and accelerated the whole process [94]. Nowadays 
nanobody generation is generally initiated through immunization of a llama or a 
dromedary. Then samples of blood are collected, and lymphocytes are purified. The total 
RNA from the peripheral blood lymphocytes is extracted and used as a template first for 
strand cDNA synthesis. Using this cDNA, VHH encoding sequences are amplified by 
PCR and cloned into the phage-display phagemid vector, leading to a nanobody. Three 
Fig. 16 Comparison of the 
structure of conventional antibody 
with the single-domain antibody 
VHH. 
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consecutive rounds of phage-display and panning (the affinity selection technique which 
selects for proteins that bind to a given target) are performed on solid-phase coated 
protein. Each round of panning results in the enrichment for antigen-specific phages 
within the pools. Tens of individual colonies are randomly selected and analyzed by 
ELISA for the presence of antigen-specific nanobodies in their periplasmic extracts. 
Alternatively, immunization can be avoided when using a naïve library. Naïve libraries are 
generated by collecting the blood of several non-immunized animals. The library is then 
obtained by the same procedure as described above [94].  
 
Fig. 17 Sequential steps of the nanobody generation and selection. 
 
The antigen specificity and affinity of nanobodies from immune libraries are of good 
quality: equilibrium dissociation constant so that low nanomolar or even picomolar are 
routinely obtained and can be further improved by molecular evolution after the selection 
procedure. 
With respect to antibodies, nanobodies are more stable, robust under stringent 
conditions, resistant to chemical and thermal denaturation and can be easily engineered 
with specific tags and fusion partners to meet diagnostics needs, contributing to the 
overall reduction of device costs [93,95]. Concerning the development of sensitive and 
selective biosensors they can be easily modified to avoid chemically reactive groups 
(primarily amines from lysines) in the vicinity of the paratope and the inclusion of such 
groups at the opposite end of the domain that permit their directional immobilization on 
the sensor surface for the maximal capturing capacity of the antigen [96]. 
Moreover, nanobodies can be selected to avoid cross-reaction with the human anti-mouse 
antibodies (HAMA), which are present in human serum and could limit the efficacy of 
antigen quantification. In fact one persistent problem that affects serum biomarker tests is 
the false results caused by the heterophilic human anti-animal immunoglobulin antibodies 
(HAIA), including HAMA, that bind by cross reactivity to animal antibodies, such those 
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commonly used in serum biomarker assays (including Her2 ELISA test), reducing the 
significance of the measurement [34]. 
Another valid alternative to antibodies is represented by nucleic acid aptamers. 
Aptamers are oligosequences selected in vitro to bind a target with high affinity. In 
particular they show highly specific binding activity resulting in dissociation constants in 
the picomolar range, as result of aptamer-target interaction based on three-dimensional 
folding patterns: depending on their sequence, temperature, pH and the presence of 
certain ions they fold into defined 3D structures and are able to bind other target 
molecules with high affinity and specificity [97].  
   
Aptamers are generally selected from a biopanning method known as SELEX (Systematic 
Evolution of Ligands by Exponential enrichment). The method starts with a random 
sequence library of ssDNA or ssRNA that spans 20–100 nucleotides in length. Near each 
random sequence region there is a constant sequences required for capture or priming. 
The initial diverse pool of aptamers is then exposed to a target molecule, with the 
expectation that a portion of the aptamers can fold in such a way that they will specifically 
bind to the target molecule. Non-binding aptamers are then washed away, while candidate 
aptamers with high target binding affinity are enriched at each selection round by PCR 
amplification (DNA aptamers) or RT-PCR followed by in vitro transcription (RNA 
aptamers). The enriched pool of aptamers is then exposed to the target again, and the 
process repeats; finally, they are tested for target binding affinity and specificity [98].  
 
Fig. 19 Generation of aptamers by SELEX. I) Aptamer pools are incubated with target for 
binding. II) Targets are thoroughly washed to remove non-binding species. III) Target-bound 
Fig. 18 Aptamer 3D structure 
formation promoted for the target 
binding. 
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aptamers are eluted from the target. IV) Amplification of candidate aptamers by PCR (DNA) or 
RT-PCR and transcription (RNA). Steps I-IV is repeated for multiple rounds to deplete non-
binders and enrich for target-binders. Following the final round of selection, binding nucleotides 
are cloned and sequenced to determine the specific nucleotide composition.  
 
Due to this specific procedure of selection, based on multiple rounds of target selection 
and enrichment, aptamer pools show high binding affinity for the target of interest. 
In addition aptamers, if compared to standard proteins, show higher stability, and ease of 
chemical modification. Aptamers production is fully automated, highly reproducible and 
low cost. Moreover, aptamers are naturally integrable in the context of DDI: DNA 
aptamer constructs are produced simply by adding a surface binding sequence to the 
aptamer during oligo-synthesis. 
  
4. THE POTENTIAL OF NANOSCALE TOOLS IN A MULTI-
INTEGRATED APPROACH FOR CANCER ASSESSMENT 
Tumors are complex and heterogeneous systems where different subclonal tumor 
populations and a variety of non-tumor cells coexist in a constantly evolving manner. The 
interactions between molecules and between cells and between molecules and cells that arise 
as a result of these alterations are even more complex [99]. Due to the complexities of cancer 
phenotypes and genotypes the characterization of specific molecular and biochemical details 
of cancer cells would be instrumental in evaluating tumors and in better driving diagnosis, 
prognosis, and therapy. 
However the clinical significance and the precise role of many receptors remains uncertain an 
not fully proved: it is a general opinion that this issue deserves further studies in large 
prospective trials, together with in vitro studies to elucidate fundamental aspects of receptor-
mediated signaling involved in cancer progression and occurrence. 
In this direction a systematic, integrated, multi-disciplinary approach to elucidate and 
correlate some molecular aspects of cancer development could be a powerful strategy 
towards more effective cancer detection and enduring therapies. The employment of a 
combination of methods and integrated analyses can lead not only to the understanding and 
modelling of the expression/activity of cancer cells receptors but also to the correlation of 
receptors interactions with their predictive value as cancer biomarkers. 
In particular we aim at assessing the correlation between overexpression, dimerization and 
activation of cancer-involved receptors and the release of receptor domains to the 
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bloodstream, in normal and cancer cells, to determine the significance of quantifiable, easily 
detectable molecular signal for tumor analysis. Such complex molecular interactions need to 
be analyzed in a wide range of length scale (from few nm to hundred microns) and call for 
merging information from advanced high-resolution and super-resolution microscopies 
(membrane protein localization, quantification and co-localization of different biomarkers) 
and nanotechnology-based diagnostic tools (high sensitivity detection of protein and vesicle 
biomarkers). 
Addressing the complexity and variability of individual tumors by means of this kind of 
innovative platforms and identifying clinically useful biomarkers will be fundamental to pave 
the way to the development of new diagnostic strategies, to help defining personalized 
therapies and produce responses of enduring efficacy [100]. 
 
Fig. 20 Example of a multi-integrated approach: exploring a wide range of length scale (from few nm 
to hundred microns) and exploiting different advanced microscopies it is possible to study specific 
characteristics of cells and their nearby microenvironment and to merge information coming from 
different analysis. 
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 RESULTS 
 
5. NANOARRAYS DEVELOPMENT AND OPTIMIZATION 1 
In this work we propose an atomic force microscopy (AFM)-based miniaturized bioaffinity 
test for the quantification of the circulating Human Epidermal Growth Factor Receptor 2 
(Her2). This approach capitalizes on other studies performed in our group [101,102,103], in 
which the full potentiality of innovative nanoarray platforms has been exploited for diseases 
biomarkers detection based on the precise confinement of high affinity antigen-binding 
molecules on a surface by means of AFM nanografting. 
To move towards clinical applications we studied here the feasibility of different binders with 
different affinity/recognition epitope. In particular, we used two different mouse IgG 
monoclonal antibodies (Abs) selected for their high binding affinity to regions outside the 
epitope recognized by Trastuzumab, suitable therefore for monitoring the disease during 
therapeutic drug treatment. Then, we explored alternative binders such as high affinity single-
domain nanobodies (VHH) (12-15 kDa) selected to bind epitopes in the Her2 hinge region. 
 
5.1 MOUSE ANTIBODY-FUNCTIONALIZED NANOARRAYS 
We used two mouse monoclonal antibodies, MGR2 and MGR3, for the setup and validation 
of the nanoarray. Both antibodies recognize with high efficiency the ECD-Her2 fragment and 
have been thoroughly characterized in immunoprecipitation experiments and by 
immmunohistochemistry using Her2 overexpressing cell lines [104,105]. Epitope binning 
experiments demonstrated that MGR2 and MGR3 bind to independent epitopes on the 
protein surface, both of which not overlapping with the epitope bound by Trastuzumab 
[105]. 
 
5.1.1 Ab-DNA conjugates production and characterization 
Towards the realization of the nanoassay, we first conjugated the two antibodies with 
ssDNA by means of a commercial click chemistry kit that exploits amine groups available 
on the Ab protein surface for covalently anchoring the DNA sequences (Fig. 21). Such 
bioconjugation is a three steps procedure in which first both protein and DNA are 
                                                   
1 “Boosting sensitivity of clinically-relevant circulating biomarker detection: a delicate balance of miniaturization, 
robustness and proper binder choice for readout optimization” E. Ambrosetti, P. Paoletti, A. Bosco, P. Parisse, D. 
Scaini, E. Tagliabue, A. de Marco, L. Casalis. Submitted to ACS Omega 
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modified with specific chemical groups, then the two modified biomolecules are made 
reacting, resulting in the formation of a stable protein-DNA bond. 
 
Fig. 21 Schematic representation of antibody-DNA conjugation reaction: first the Ab is 
functionalized with S-HyNic group and DNA is linked to S-4FB group. Then these two groups 
react to provide a covalent Ab-DNA conjugate. 
 
This method shows many advantages: it is a highly efficient (>80% of the protein is 
conjugated) and high yielding reaction. The produced conjugate is extremely stable and 
the reaction conditions are mild avoiding protein denaturation and no metals, oxidation 
or reducing reagents are needed. Moreover the modifications made both on the protein 
and on the oligonucleotide are quantifiable using colorimetric assays. This helps in 
facilitating the reproducibility of the reaction by accurate characterization of all 
components. Finally the total degree of DNA-protein functionalization is quantifiable by 
UV spectrophotometry, since the bis-arylhydrazone group formed in the DNA-protein 
anchoring points adsorbs at a specific wavelength (354 nm). In this way, calculating the 
ratio between the determined concentration of bis-arylhydrazone groups and the relative 
concentration of protein it is possible to simply obtain a quite accurate estimation of the 
number of conjugated DNA sequences per antibody. It has to be underlined that all 
conjugation reactions result in a mixture of reaction products consisting of the desired 
conjugate along with some un-conjugated modified oligo. For this reason, the conjugation 
reactions are purified using size exclusion chromatographic methods. 
To avoid multiple strands attached to a single Ab, sterically limiting the binding affinity to 
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the target, we optimized the original conjugation protocol obtaining on average two-three 
strands per protein, and in any case never more than four. This low degree of DNA 
functionalization is desirable in order to have a lower impact on Ab binding capability: all 
primarily amines from lysines exposed on protein surface are potentially available for the 
modification. Decreasing the number of DNA sequences conjugated per protein reduces 
the probability to have one DNA attached to the lysine residues in the vicinity of the 
paratope, potentially affecting the antigen recognition [106]. 
 
Fig. 22 Schematic representation of Ab functionalization by means of DNA sequences. The low 
number of DNA tails anchored to the Ab (A) has a lower influence on its interaction with the 
specific target with respect to an Ab functionalized with a high number of DNA sequences (B). 
 
After conjugation, SPR experiments have been performed to understand how the 
functionalization affects the Ab affinity for the specific antigen.  
 
Fig. 23 Schematic representation of the different SPR experimental approaches. In the first assay 
configuration (A) ECD-Her2 is the ligand covalently immobilized on CM5 surface and Ab (1) or 
Ab-cDNA conjugate (2) are the analyte run over the surface. In the second assay configuration 
(B) the ssDNA is attached on streptavidine (SA) surface through streptavidin-biotin bond; then 
the ligand Ab-cDNA conjugate is immobilized by hybridization and the ECD-Her2 is run as 
analyte over the surface. 
 
In the first SPR experimental design (Fig. 23A), ECD-Her2 was immobilized by amine 
coupling reaction to the dextran matrix on the chip and the apparent binding affinities of 
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Abs and Ab-conjugates used as analytes were assessed. We have to point out that in the 
specific experimental configuration the ECD-Her2 amine groups involved in the 
interaction with the dextran matrix are randomly explored. Due to this immobilization 
process some antigen molecules could have the region of binding with the Ab partially or 
totally not available, causing an underestimation of the affinity determined in such 
measurement. However these experiments have a comparative, qualitative meaning. The 
KD values found and summarized in Table 1 indicated that the DNA functionalization 
significantly affected the binding capability of the MGR2 and MGR3 binders, lowering 
their binding affinity 10 and 6.5 times respectively, probably due to the steric hindrance of 
DNA moieties. 
 
Table 1 Summary of binding affinity constant (KD - nM) of monoclonal Antibodies (alone or 
conjugated) for ECD-Her2, measured by SPR technique. 
 
To better mimic the working conditions of our nanoarray, we performed SPR 
measurements using an alternative configuration (Fig. 23B). First the biotinilated-ssDNA 
was attached to the chip through biotin-streptavidin coupling (using a dextran matrix 
functionalized with streptavidin); then it was hybridized with the Ab conjugated with the 
complementary ssDNA strand. ECD-Her2 was used as analyte. This approach showed 
an easier interaction between antigen and antibodies and a KD in the low nanomolar 
range (MGR2 17.1 + 1.1 nM; MGR3 30.4 + 2.3) ensuring that efficient antigen 
recognition is enabled in the nanoarray configuration. All the SPR results are reported in 
Table 1. 
 
5.1.2 ECD-Her2 detection: calibration curve and sensitivity 
For nanoscale functionalization, we combined DNA nanografting, fine-tuning the 
process to optimize the density of patterned biomolecules [102], and the semisynthetic 
Abs-DNA conjugates immobilization through DDI with high efficiency, site-selectivity 
and reversibility [86,107] (Fig. 24).  
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Fig. 24 Schematic representation of the DDI strategy to immobilize antibodies on the micro-
sized DNA-based biosensor. 
 
We then capitalized on AFM topographic imaging to visualize any change in the 
nanopatches surface topography occurring upon interaction with the antigen, with sub-
nanometric resolution, and to quantify the number of biorecognition events, as 
successfully demonstrated in previous works published by our group 
[86,101,102,107,108]. Topographic height variations of the nanopatches have been 
measured with AFM in gentle contact mode in liquid using a softer AFM tip (see 
Materials and Methods); applying during measurement a force at the minimum stable 
value (0.1 nN) guarantees the minimum perturbation and hence the precision of the 
molecular height detected [102]. It is worth to point out that gentle contact imaging, while 
not suitable for single biomolecules on surfaces, is appropriate to image laterally packed 
2D DNA NAMs/SAMs, and that provides higher resolution with respect to NC or 
tapping imaging modes (as from the Lennard-Jones potential of Fig. 9). 
The height of the patch is measured as the average of all the values recorded in the entire 
patch area, at each step of the assay fabrication (i.e. ssDNA nanografting; DDI of Abs-
DNA conjugates; antigen binding), with respect to the surrounding SAM of bio-repellent 
alkanethiols. To protect the surface from non-specific biomolecules binding, we first 
protected the gold film with a self-assembled monolayer of alkanethiols (C11) modified 
with 6 ethylene-glycol (EG) units at the end. We named it TOEG6 SAMs (top-terminated 
ethylene-glycol 6 alkanethiol SAM). The hydrophilic nature of EG portion of the film 
keeps the hydration shell of any biomolecule in solution intact, preventing non-specific 
adsorption [110,111,112]. This has been tested in our experiments through roughness 
measurements: this value was approximately 0.2 nm, and did not change at any level of 
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device implementation. The anti-fouling nature of the TOEG6 SAM allows our device to 
work even in complex matrices, avoiding false positive results, as mentioned in the 
Introduction section.  
The binding of 10 nM ECD-Her2 over MGR2 and MGR3 antibody nanostructures, 
respectively, is reported in Fig. 25. The images of the nanopatches (Fig. 25A and 25D) 
show the height increase at each step of the assay formation, till antigen binding (brighter 
is the colour higher is the nanoassembly height versus the reference SAM). Relative height 
variations determined from the AFM images, with respect to the TOEG6 SAM (2.4 ± 
0.3 nm [109]), are visualized showing the topographic lines profiles (Fig. 25B and 25E). 
Relative height values at each steps of nanoarray development are given in tables (Fig. 
25C and 25F). 
 
Fig. 25 ECD-Her2 nanoarray detection by means of MGR2 (A, B, C) and MGR3 (D, E, F) Abs, 
respectively. (A, D): AFM images across the nanopatches after DNA immobilization, antibody 
loading via DDI and binding of the antigen. (B, E): Relative topographic line profiles from AFM 
images A, D (light blue: DNA nanografting; red: Ab-conjugate immobilization via DDI; green: 10 
nM ECD-Her2 binding). (C, F): Mean and SD values of the patch heights as measured from the 
line profiles across the nanopatches in correspondence of the colored areas of images A, D at 
each step of the experiment.  
 
In all cases, the average height of the thiol ssDNA’s nanopatches (Fig. 25B and 25E, blue 
lines) is close to 3.0 nm. This experimental value is in agreement with what expected for 
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“low density” nanografting conditions (S/A = 0.3-0.6) in which the vertically standing 
thiolated DNA molecules are below the highest packing limit (the height of the fully 
stretched DNA in this specific ionic strength conditions (1 M NaCl) is around 6 nm 
[109]) and therefore not fully vertically stretched by the electrostatic repulsive forces 
[113]. This DNA density has been identified as the optimal one to accommodate the 
steric hindrance of the subsequently immobilized antibodies and to make their binding 
site easily accessible to the analyte in solution. In fact the ssDNA density affects 
hybridization of the conjugate and so the detection of Her2. As shown in Fig. 26 only at 
“low DNA density” it is possible to obtain an efficient hybridization of Ab-cDNA (height 
increase after conjugate incubation); this is due to the fact that the large dimension of the 
antibody requires spacing between ssDNA molecules in order to avoid steric hindrance 
problem and to efficiently bind via DDI. All the data of Fig. 25 are relative to this class of 
“low DNA density”. 
 
 
Fig. 26 Histogram created collecting different experiments (number of experiments: 30); data are 
subdivided into three classes of density (S/A = 0.3 - 0.6 - 2.6). Error bars represent the standard 
deviation; red: grafting of ssDNA; green: hybridization of Ab-DNA conjugate. 
 
 
DNA-antibody conjugates immobilization determines a height increase of roughly 4-5 
nm (Fig. 25B and 25E, red lines). The further height increment after the incubation with 
ECD-Her2 (Fig. 25B and 25E, green lines) clearly indicates the efficient antibody-
dependent antigen capture. 
Next, the nanodevice has been used for the quantitative determination of the target. We 
calculated the affinity calibration curve for both MGR2 and MGR3 assuming that the 
variation in height across the nanopatches is proportional to the amount of analyte 
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bound to the ligand. Height variations were plotted versus ECD-Her2 concentrations 
ranging from 200 pM to 100 nM in the case of MGR2 and from 1 nM to 300 nM in the 
case of MGR3 (Fig. 27). 
 
 
Fig. 27 ECD-Her2 binding curves on MGR2- (left) and MGR3-DNA (right) conjugates 
immobilized on the nanoarray, respectively. The average values of height variation (Δh) detected 
on nanopatches (n=4) have been plotted versus ECD-Her2 concentration. Data have been 
analysed with Hill equation sigmoidal fitting and KD determined. 
 
 
The sigmoidal distribution of data is in agreement with the saturable binding isotherm 
for a receptor-ligand binding equilibrium and was fitted with the Hill equation [114], 
obtaining a dissociation constant KD (the parameter that defines the binding affinity of 
two molecules) in the low nanomolar range for both MGR2 (KD = 3.3 ± 0.9 nM) and 
MGR3 (KD = 17.0 ± 10.7 nM). From data of Fig. 27, we determined a limit of sensitivity 
(LoB – see Materials and Methods) of about 1 nM for the higher affinity MGR2 and 3 
nM for MGR3. Although good, these sensitivity values need to be improved in order to 
reach the current FDA-approved serum Her2 level cutoff (≅  200 pM); we plan to 
complete the optimization moving from nanoarray validation to optimization phase, 
where sensitivity and the proper binder choice will be the crucial aspects of the study. 
To validate the nanoarray results, we set up a standard ELISA assay in which different 
concentrations of the same Abs were added in ECD-Her2-coated wells (Fig. 28).  
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Fig. 28 Indirect ELISA. (A) Schematic representation of the assay. (B) Determination of binding 
affinity between ECD-Her2 and Antibodies (MGR2 and MGR3). Absorbance is measured at 450 
nm and plotted as a function of Ab concentration. Data are fitted with Hill equation. 
 
The dissociation constant values found with this assay (MGR2: KD = 2.3 ± 1.3 nM; 
MGR3: KD = 23.0 ± 6.2 nM) were in very good agreement with those found with the 
nanoarray (Confidence Level (CL) = 0.74 and 0.69 respectively). The different 
experimental setup justifies the quite higher KD value obtained with SPR in the 
nanoarray–like configuration with respect to the nanoarray and ELISA; nonetheless the 
value in the low nanomolar range guarantees an efficient antigen recognition in a 
nanoarray-like configuration.  
 
5.1.3 Comparison with Trastuzumab-functionalized nanoarray detection 
Since Trastuzumab is the humanized Ab used as therapeutic agent in standard clinical 
practice and as such it has been chosen and optimized to bind the target with high 
affinity, it is significant to compare the KD of our mouse monoclonal Abs with that one 
of Trastuzumab, functionalized and immobilized on the nanoarray surface with the same 
approach used for MGR2 and MGR3 and starting also in this case from a “low DNA 
density”. As shown in Fig. 29 for Transtuzumab we found KD = 3.2 ± 0.01 nM that is 
perfectly comparable with the value found for MGR2 and not so far from that one of 
MGR3; the KD of Trastuzumab-Her2 interaction reported in other works [86,110] varies 
depending on the technique used for the affinity determination. The values span from 
picomolar (in vitro assay in solution) to low nanomolar (cell-based assay); the affinity in the 
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low nanomolar range found with our “surface assay” demonstrates that our strategies of 
functionalization and immobilization of an high affinity antibody preserved anyhow a 
range of binding capability sufficient for a sensitive detection. 
 
Fig. 29 Binding curve of ECD-Her2 and Trastuzumab conjugate immobilized on nanoarray 
surface: the average values of height variation (Δh) detected on nanopatches have been plotted 
versus ECD-Her2 concentration. Data have been analyzed with Hill equation sigmoidal fitting. 
 
5.2 CAMELID NANOBODY-FUNCTIONALIZED NANOARRAYS 
In alternative to conventional antibodies, we exploited here camelid nanobodies, recombinant 
molecules that can be easily engineered at precise and unique residues to avoid multiple and 
heterogeneous labeling and loss of activity. Moreover, due to their reduced dimensions, 
nanobodies can be used to prepare functional surfaces with higher ligand densities compared 
to conventional antibodies, hence simultaneously increasing the active detection surface and 
avoiding steric hindrance. In particular, it has been demonstrated the advantage of producing 
nanobodies specialized for ECD-Her2 biorecognition with a free C-terminal cysteine 
available for single-point maleimide functionalization [115]. This approach enables 
functionalization using residues not involved in the Ab paratope consequently preventing 
modifications of the Ab-antigen binding features. The llama nanobody EM1 has been 
selected in vitro from a naïve library [116] using the same strategy reported in Djender et al. 
[117]. It binds to an ECD-Her2 epitope close to the one recognized by Trastuzumab.  
 
5.2.1 VHH-DNA conjugates production and characterization 
EM1 was expressed with a free C-terminal cysteine and covalently linked with a 
maleimide-ssDNA construct (Fig. 30).  
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Fig. 30 Schematic representation of nanobody-DNA conjugation reaction: the Cys thiol group at 
the C-term of VHH reacts with the maleimide group attached to the 5’ end of the DNA 
sequence. 
 
Similarly to what discussed in paragraph 5.1.1, we measured the binding properties of 1:1 
EM1-ssDNA conjugates by SPR (in the nanoarray-like configuration), finding a KD of 3.4 
± 0.3 nM.  
 
5.2.2 ECD-Her2 detection: calibration curve and sensitivity 
We proceeded with nanobody-DNA conjugate nanoscale immobilization on the gold 
surface with the same DDI approach used for MGR2 and MGR3 antibodies. The two 
first preliminary steps (grafting of ssDNA, hybridization of DNA-nanobody conjugate) 
were optimized according to the small dimensions of VHHs (2x2x3 nm; ∼ 15 kDa 
[93,94]). Notably, the density of grafted ssDNA sequences has a great impact on the 
hybridization of the conjugate and consequently on the detection of Her2. While in the 
case of full antibodies low DNA densities are needed to avoid steric hindrance effects, for 
nanobodies we should pay attention not to leave voids in the nanografted DNA SAM 
into which the nanobody itself could hide, becoming unavailable for the interaction with 
the analyte (Fig. 31A). On the contrary, at high DNA density the nanostructures are well 
packed and the binder stands up over the DNA layer surface in the right configuration 
(Fig. 31B). 
 
Fig. 31 Schematic representation of DNA density impact on VHH-DNA conjugates 
configuration over the gold surface. 
 
This explains why, as shown in the Fig. 32, conditions for highly performing target 
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detection were reached only at high density. 
 
 
Fig. 32 Histogram created collecting different experiments (number of experiments: 30); data are 
subdivided into classes of density related to ssDNA relative height. Error bars represent the 
standard deviation; red: grafting of ssDNA; green: hybridization of Nb-DNA conjugate. 
 
Tuning DNA density and DDI conditions depending on the dimension and the specific 
characteristics of the binders to optimize detection performance in the immunoassay is a 
unique feature of AFM nanografting. 
Once optimized the immobilization conditions we performed ECD-Her2 detection with 
EM1 conjugate nanostructures, following the same experimental procedure used for Abs 
(ssDNA grafting, DDI-driven conjugate immobilization and target binding). As a 
representative case we report the results related to the detection of 1 nM ECD-Her2 (Fig. 
33).  
 
Fig. 33 Detection of  ECD-Her2 on nanoarray. Images of  the nanopatches on the gold surface (A) 
and their relative height topographical profiles (B). (C) Average and Standard Deviation values of 
the height are measured across the nanopatches at each step of  the experiment (light blue: 
grafting of  ssDNA; red: hybridization of  VHH-DNA conjugate; green: ECD-Her2 1 nM 
incubation). 
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The measured relative height of  the “high density” grafted ssDNA is 4.5 ± 0.2 nm, a 
value that describes the highest packing nanopattern in which the thiolated DNA 
molecules are vertically standing [109]. 
As provided for MGR2 and MGR3 Abs, we determined the EM1-ECD-Her2 binding 
affinity curve with different analyte concentrations ranging from 200 pM to 30 nM (Fig. 
34). 
 
Fig. 34 Binding curve of  ECD-Her2 and EM1 nanobody conjugate immobilized on 
nanoarray surface. The average values of  Δ height detected on nanopatches (n=8) have been 
plotted versus ECD-Her2 concentration; data have been analysed with Hill equation 
sigmoidal fitting and KD determined. 
 
Also in this case, we fitted data with Hill equation, determining a dissociation 
constant value of KD = 1.8 + 0.6 nM, lower than for MGR2. The S/N ratio improves 
substantially moving from antibody- to nanobody-binders, probably because the 
higher density DNA layer underneath increases the mechanical robustness of the 
device: the readout in fact is based on a mechanical probe which, although operated at 
minimum force, still reflects the mechanical resistance of the surface. Overall the limit 
of sensitivity decreases to about 200 pM, pushing the nanoarray sensitivity to a level 
comparable to the cutoff value of 15 ng/ml (≅ 200 pM) which is commonly used in 
clinic for Her2 positive breast cancer assessment [34,36]. Although this result is 
already very sound, we would like to stress here the fact that in principle, the 
nanoarray sensitivity could be further improved up to the low picomolar range by 
exploiting new computational/experimental protocols for accelerating the evolution 
of new biosynthetic binders with increased affinity and specificity. In this direction we 
plan to identify in silico customized VHHs for specific (non-immunogenic) epitopes of 
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Her2 fragments by means of computational design [118] and/or high-affinity peptides 
for chosen epitopes of target proteins by stochastically exploring their sequence and 
structure space. 
 
5.3 REGENERATION OF THE NANOARRAY 
Regeneration is the process of removing bound antigen from the Ab/Nb functionalized 
nanoarray surface after each sample analysis incubation, in order to prepare the device for the 
next analysis cycle. 
Efficient regeneration is a crucial step for a successful assay: a complete regeneration and the 
maintenance of the binding activity from the surface guarantee the performance of the assay 
and a longer useful lifetime of the nanoarray. Regeneration of the surface with a chemical 
treatment could be avoided if the antigen dissociates fast enough and all molecules may be 
removed within a reasonable time simply by washing with buffer. When the spontaneous 
dissociation is not sufficient it is necessary to determine suitable regeneration conditions. 
We tested many regeneration conditions evaluating the dissociation of a high ECD-Her2  
concentration (50 nM) from MGR2-functionalized nanoarray: low pH (1.5–3), high pH (10), 
high ionic strength (5 M NaCl) solutions.  
Among the different chemical treatment tested we identified as best condition the use of 
Glycine-HCl 12mM pH 2.0; it leads to a successful result since, as shown in Fig. 35, after 
such treatment the height across the nanopatch recovered almost the same value the 
conjugate only present on the surface, before ECD-Her2 binding. In another step, we also 
verified that the conjugate after regeneration doesn’t lose its capability to rebind Her2. 
 
Fig. 35 Regeneration of the nanoarray. (A) Relative height of the nanopatches at each step of  the 
experiment (grafting of  ssDNA; hybridization of  MGR2-DNA conjugate; ECD-Her2 50 nM 
incubation; regeneration with Glycine-HCl 12mM pH 2.0, second incubation with ECD-Her2 50 nM) 
is plotted. (B) Average and Standard Deviation values of  the height are reported on the table. 
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The possibility to regenerate the nanoarray not only proves the robustness of the molecular 
assembly on the surface but also offers a great advantage in the experimental tests to setup 
the assay, since it allows performing different trials avoiding the wastage of materials and 
molecular reagents. Although for clinical devices a disposable approach is preferred, during 
their optimization phase the capability to regenerate the active surface might be strongly 
helpful.  
 
5.4 ECD-Her2 DETECTION IN STANDARDIZED HUMAN SERUM 
As intermediate step to move towards detection in blood serum samples we tested the 
capability of  the nanoarray to recognize the target of  interest in human serum. We chose to 
work with standardized human serum, which in terms of  protein content (60% IgG antibody 
and 20% albumin w/w with respect to the total protein content) mimics the serum of  human 
patients. First, we assessed unspecific protein binding to the nanobody-functionalized patches 
and/or to the surrounding thiol carpet. As shown in Fig. 36A we observed a negligible 
increase of  patch height (about 0.2 ± 0.4 nm) upon moving from PBS to standardized human 
serum (in absence of  antigen). Also, the roughness of  the biorepellent SAM carpet did not 
change sensitively (Rms = 0.23 nm and 0.25 nm, before and after serum incubation, 
respectively). This is a crucial result, since the TOEG6 SAM is for us the reference level to 
assess all the changes on the sensitive part of  the assay. The biofouling properties of  the 
TOEG6 SAM seem to be maintained also when measurements are performed in matrices 
more complex then PBS. Upon addition of  1 nM ECD-Her2 to the serum, and using a 
nanoarray configuration with a high-density NAM of  nanobodies, we observed a relevant 
patch height increase of  1.3 nm (Fig. 36A). Considerably this value is the same of  the 
differential height increase value Δh extracted in correspondence to an ECD-Her2 
concentration of  1 nM in the calibration curve obtained with the recombinant protein in 
buffer solution. This further proves that our nanoarray is capable to filter the background 
noise of  a biological sample and recognise the specific biomarker of  interest.  
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Fig. 36 ECD-Her2 detection in standardized human serum. (A) Nanopatches height variation (n=8) 
on nanobody-immobilized nanoarray incubated with standardized human serum with or without 
ECD-Her2 1 nM; the two variations are statistically different (p<<0.05). (B) Extrapolation of  the 
height increase expected from the nanobody-based calibration curve presented in Fig. 34. 
 
As additional test to validate the ECD-Her2 detection in standardized serum we repeated the 
measurements using test explained before using a NAM of  Abs as binders (Fig. 37). In this 
case we observed a quite higher increase of patch height (about 1.5 ± 0.7 nm) upon moving 
from PBS to standardized human serum, in the absence of antigen. This evidence could be 
explained by the fact that the density of the DNA patch is lower with respect to that one 
created for nanobody-functionalized nanoarray. The presence of a certain distance between 
DNA molecules could allow the permeation of serum protein and therefore determine a 
slight aspecific binding. However the binding affinity of MGR2 is preserved: upon addition 
of 10 nM ECD-Her2 to the serum another significant patch height increase of 1.5 nm (Fig. 
37A) was obtained.  
 
Fig. 37 ECD-Her2 detection in standardized human serum. (A) Nanopatches height variation (n=8) 
on MGR2-immobilized nanoarray incubated with standardized human serum with or without ECD-
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Her2 10 nM; the two variations are statistically different (p<0.05). (B) Extrapolation of  the height 
increase expected from the MGR2-based calibration curve presented in Fig. 27. 
 
Also in this case the differential height increase has been compared with that one extrapolated 
from the calibration curve obtained using the recombinant protein in buffer solution; the 
slight discrepancy could be due to the presence of a non-specific binding of the serum alone, 
as explained before, that affects somehow the measurement.  
Therefore if we consider the two assays, performed with nanobody- and antibody-
functionalized nanoarray respectively, it is evident that reducing the non-specific binding by 
the molecular constituents of the complex matrix in which the biomarker of interest is 
dissolved is a crucial step to improve the precision of the quantitative analysis. 
 
5.5 MULTIPLEXED DETECTION 
To further challenge the nanoarray and to prove its validity in clinical practice, we performed 
a preliminary multiplexing analysis, testing the simultaneous detection of ECD-Her2 and 
uPA, another relevant breast cancer biomarker.  
Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved 
in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1); 
in the last years several retrospective and prospective studies have shown that elevated levels 
of uPA and PAI-1 in breast tumor tissue are prognostic biomarkers as powerful predictors of 
poor patient outcome, including adverse outcome in the subset of breast cancer patients with 
lymph node-negative disease [119]. Moreover it has been demonstrated that in some cases 
uPA is secreted as pro-urokinase (53 kDa) and released in bloodstream [120], hence 
representing a good candidate as circulating biomarker. 
As shown in Fig. 38, we grafted two DNA sequences of the same length (cF5 and cF9, see 
Materials and Methods section) complementary to the conjugated tail of, respectively, the α-
uPA Ab and EM1 VHH. Then we introduced the two conjugated binders and the respective 
antigens, following the order reported in the legend of Fig. 38B (from the top to the bottom). 
Relative height profile variations across the functional spots are reported in Fig. 38B and in 
the tables of Fig. 38C. Following the line profiles it appears evident the high selectivity of the 
DDI process, as well as the antigen recognition by the relative binders: no cross-talking can 
be measured in the multiplexing nanoarray.  
Also, the unchanged roughness of the thiol SAM carpet at each step of biomolecules 
incubation indicates that no non-specific binding over the surface occurred, pointing again 
towards the powerful anti-fouling properties of our TOEG6 SAM. 
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In quantitative terms, we can see that the final height increase over the cF9 spots upon 
loading of 20 nM ECD-Her2 consists of about 4 nm. This value is compatible with the 3.3 
nm Δh value extrapolated from the calibration curve of Fig. 34, for the same concentration 
over a single VHH binder-functionalized surface. Moreover, the Δh values corresponding to 
the same concentration of uPA and ECD-Her2 (20 nM) are of 2.7 nm and 4 nm respectively. 
This can be explained taking into account the different dimensions of the two proteins (53 
kDa uPA and 72 kDa ECD-Her2). 
The high selectivity of the binding of the two Ab-Ag pairs working in parallel is then a 
promising result that ensures the multiplexing nanoarray implementation in real conditions. 
 
Fig. 38 Multiplexed detection of  two different biomarkers (ECD-Her2 and uPA) on the same surface. 
(A) Schematic representation of the DDI immobilization of the binders on the DNA-based biosensor 
and the subsequent detection of the antigens. Height variations of the two separated sets of DNA 
nanopatches (cF5 and cF9) after each step of incubation of biomolecules (the two different conjugates 
αuPA Ab-F5 and VHH EM1-F9 and then the two different biomarkers ECD-Her2 and uPA 20 nM) 
are visualized by topographic profiles (B) and by histograms (C); Average and Standard Deviation 
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height values (n=4) are reported on the tables. Grey columns correspond to controls (no expected 
height increase). 
 
 
5.6 FLUORESCENCE EXPERIMENTS 
So far we have demonstrated that our nanoarrays work in a sensitive and antigen-specific 
manner, with the clear advantage over the standard ELISA platforms to use small volumes 
and, more importantly, to require only one binder per antigen. In order to perform an 
additional validation of our nanoarray, and convince about the selectivity for the specific 
antigen, we compared the single protein-binder topographic measurements approach and the 
conventional nanoarray-based sandwich approach with florescent readout. The goal is to label 
the nanostructures with a fluorescent molecule as unequivocal proof of the presence of the 
target bound on the surface.  
Moreover we like to demonstrate that a fluorescence-integrated sandwich nanoarray allows 
performing epitope binning of the binders by analysing the pattern of simultaneous or 
competitive action of different couples of binders.  
 
5.6.1 Validation of nanoarray topographic measurements 
As a first approach, we used an “indirect” sandwich configuration (Fig. 39A), more 
similar to classical ELISA setups. We first immobilized the Abs on the surface and, after 
ECD-Her2 capture, we added another Ab specific for a further independent ECD-Her2 
epitope. The fluorescence signal was obtained using a fluorescently-labeled secondary α-
mouse Ab. From Fig. 39 it is possible to perceive the very good matching between 
topographic and fluorescence data in this “indirect” nano-sandwich approach.  
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Fig. 39 Fluorescent visualization of ECD-Her2 captured by the nanoarray. (A) Schematic 
representation of molecular nanoassembly on the gold surface together with AFM images of the 
patches at each step of incubation (sequentially: ssDNA, Trastuzumab-DNA conjugate, 200 pM 
ECD-Her2 and MGR2) at different densities of grafted ssDNA (indicated with different colors, 
see text). Scale bar 2 μm. (B) Fluorescent image of the patches described in (A) after the incubation 
with anti-mouse Ab labeled with the fluorophore Alexa488. Scale bar 2 μm. (C) Height increase 
values recorded with AFM topographic analysis after each incubation step on the patches and 
fluorescence values intensity measured as pixel counts are reported in the two tables; fluorescence-
AFM topography correlation plot (number of independent patches: 4 for each grafted ssDNA 
density). 
 
The successive incubation steps were: i) ssDNA; ii) Trastuzumab-DNA conjugate; iii) 
ECD-Her2; iv) MGR2; v) secondary α-mouse fluorescent Ab. Notably we confirmed, by 
means of fluorescence measurements, that even a low topographic height increase (0.2 - 
0.5 nm) corresponds to a measurable fluorescent signal, validating the occurrence of 
binding of very low target concentrations (200 pM). Moreover, as demonstrated by the 
values reported on the tables and in the AFM-fluorescence correlation graph of Fig. 39C, 
the fluorescence signal is linearly scaling with the topographic signal and with the density 
of the ssDNA grafted on the surface, which in turn correlates with the binder density and 
therefore the total amount of captured target molecules. This validates the quantitative 
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analysis performed through topographic measurements across the nanopatches of the 
nanoarray, that anyhow will be carried on without this fluorescent additional tool, 
confirming that our single-binder assay retains all the potentiality of ELISA with the great 
advantage of simplicity, cost, efficiency and avoiding the possible artifacts of the 
fluorescent readout. 
 
5.6.2 “Epitope mapping” studies 
In addition, the fluorescence-integrated sandwich-nanoarray setup might be useful to 
obtain important information about protein epitopes recognized by the different binders. 
For that we used the same “indirect” approach described before, but also a simplified 
“direct” sandwich approach by exploiting the easy functionalization of the VHH EM1: as 
a first binder we used a mouse/humanized Ab while the second one was chosen to be the 
GFP-conjugated VHH. The two configurations are reported in the cartoons of Fig. 40 
together with fluorescence images relative to different combinations of binders in the 
sandwich. 
Fig. 40 Fluorescence images obtained with different combinations of Ab/VHH “sandwich” 
assay. For images related to the “indirect” configuration (A, B and C) the first Ab of the 
“sandwich” is indicated in purple and the second in blue; for the “direct” configuration (D, E and 
F) the first Ab of the “sandwich” is indicated in purple. Next to each fluorescence image the 
schematic representation of the patches position (violet squares) is reported. Scale bar 2 μm. 
 
 62
We noticed that the fluorescence signal coming from the secondary antibody is generally 
sharper with respect to the GFP fluorescent signal on the VHH. This could be related to 
the different fluorescence quantum yield, to the amplification effect due to the secondary 
Ab, and also to the different dimensions of the two systems, being the VHH four times 
shorter than Abs and therefore closer to the gold surface, which could partially quench 
the fluorescence signal. 
That given, we used the VHH-related  “direct” configuration (Fig. 40D-F) to test its 
relative epitope on ECD-Her2 recognition. While a fluorescence signal was visible when 
coupled to MGR2 (Fig. 40D) and Pertuzumab (Fig. 40F), no fluorescence was observable 
when coupled to Trastuzumab (Fig. 40E). This fact indicated that VHH EM1 and 
Trastuzumab bind on close/overlapping epitopes and that these are totally independent 
from the one recognized by Pertuzumab, as reported in the literature [41]. Concerning 
MGR2, whose epitope has not been mapped yet, our preliminary experiments indicate a 
simultaneous binding with the VHH and therefore a non cross-reactivity with it. 
Translating results of Fig. 40D and 40E, we could also conclude that MGR2 and 
Trastuzumab recognize different epitopes. This is confirmed by result obtained with the 
“indirect configuration” (Fig. 40C) where we observed the presence of the fluorescence 
signal in correspondence of the concomitant binding of MGR2 and Trastuzumab proving 
that the MGR2-functionalized nanoarray is suitable for monitoring the response to 
therapeutic treatment with this humanized Ab.  
With the “indirect assay” we also confirmed the simultaneous binding of MGR2 and 
MGR3 (Fig. 40A). Data in Fig. 40B relative to the sandwich binding of MGR2 and VHH 
are apparently contradicting data of Fig. 40D, in which the same couple of binders is used 
but just in the reverse order. This could be explained by the fact that due to the small 
dimensions of nanobody, the Ab accessibility to the analyte would be limited as 
consequence of the proximity to the surface (Fig. 41).  
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Fig. 41 Schematic representation of the two different likely configurations of the 
simultaneous binding of MGR2 and VHH on ECD-Her2. 
 
Combining the evidences of both direct and indirect configuration with these two binders 
we can however assume that the binding sites of VHH EM1 and MGR2 on ECD-Her2 
are most likely very close.  
The characterization of the epitope recognized by the binders employed in the nanoarray 
is also crucial to identify the best molecule capable to discriminate the soluble Her2 
variant associated with pro-oncogenic activity, by identifying the specific neoepitope 
generated upon proteolytic cleavage (the primary cleavage site of Her2 has been located at 
amino acid position 647–648 and a minor cleavage site has been located at amino acid 
position 644–645 [33]) and hence improving the specificity of a serum Her2 assay. The 
evidences obtained up to now with our nanoarray fluorescence approach are not 
sufficient to prove this specificity. However, we plan to exploit in silico engineering of the 
nanobodies to search for higher affinity binders highly specific only for the cleaved form 
of Her2, to overcome the limits of the current FDA-approved serum Her2 immunoassay. 
Moreover such kind of binder will also help to discriminate the fraction of ECD-Her2 
related to the Her2-expressing exosomes, another important class of potential biomarkers 
for Her2-positive breast cancer, whose role needs further elucidation.  
These experiments demonstrated that nanografting-based nanoarrays, beyond their 
potentiality as detection tool, can serve as an alternative approach, complementary to 
more conventional methods, for identifying the molecular determinants of antibody-
antigen recognition. 
 
6. APTAMERS: A PRELIMINARY STUDY TO ASSESS ITS 
FEASIBILITY AS INNOVATIVE NANOARRAY BINDERS 2 
To increase the nanoarray assay sensitivity, in this part of the study, we tested other high 
affinity protein binders, the nucleic acid aptamers, to exploit them as active recognition 
elements of miniaturized DNA-based biosensors. 
As a proof of principle, in this study we used an extensively investigated aptamer for 
thrombin (THR) [121] that shows a well-characterized structure and binding properties (KD = 
50 nM), confirmed by several studies [123,127]. We modified aptamers with a DNA tag 
                                                   
2
 “Miniaturized Aptamer-based Assays for Protein Detection” A. Bosco, E. Ambrosetti, J. Mavri, P. Capaldo, L. 
Casalis. Chemosensors.  2016; 4:18. 
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(cDNA), meant to hybridize to micron-sized surface-grafted complementary DNA 
monolayers, to create the desired functional areas. We carefully optimized the immobilization 
strategy to implement DNA-modified aptamers onto the DNA-based miniaturized AFM 
nanoarrays. As already explained in the experiments related to antibodies/nanobody 
functionalized nanoarray, this sensor platform has been designed and developed to allow for 
the sensitive detection of biomolecules in small sample volumes. 
 
Fig. 42 Cartoon representing the DDI strategy to immobilize an aptamer on the micron-sized DNA-
based biosensor.  
 
By AFM nanografting we confined nanospots of thiol-modified single-stranded DNA 
monolayers inside a bio-repellent, self-assembled monolayer (SAM) of oligoethyleneglycol-
terminated alkanethiols. The density of the DNA-confined SAM can be tuned via nanografting, 
and adjusted to the steric requirements of this specific biorecognition elements. On such active 
DNA nanospots, the aptamer-DNA conjugate is then loaded through Watson-Crick base-
pairing, in a process known as DNA-directed immobilization.  
Two THR-binding constructs were proposed in this regard: a simple design consisting of the 
aptamer region on the 5′ side, extending with the immobilization region complementary to 
the DNA grafted monolayer on the 3′ side (Fig. 43A); a second design similar to the first one, 
but containing a hexaethilenglycol-spacer (HEGL) between the two regions to improve the 
functionality of aptamer binding site (Fig. 43B).  
 
 65
Fig. 43 Thrombin aptamers sequences, with (A) and without (B) hexaethilenglycol-spacer, hybridized 
to the complementary ssDNA on the surface.  
 
As stated in several works, the use of polyethyleneglycol groups can significantly improve 
biorecognition sensitivity by reducing nonspecific interactions and steric hindrance effects 
[124,125]. In both cases the surface linking oligo sequence (with an alkanethiol linker to bind 
to the gold surface), and the complementary one on the aptamer side, were carefully selected 
to have minimal influence on the protein binding—aptamer region in order to avoid possible 
interferences during aptamer immobilization and then on the aptamer binding interaction 
with THR. 
 
6.1 PRELIMINARY AFFINITY CHARACTERIZATION OF THE DNA-
APTAMER CONSTRUCT 
All of the experiments were carried out using a buffer (THR buffer) that folds the aptamer in 
the functional conformation for the recognition of the antigen. To this aim, preliminary tests 
were carried out to check that both the affinity of the DNA-aptamer construct for the surface 
immobilized complementary strand and the one for the ligand were preserved. In this regard an 
estimation of hybridization affinity between the thiolated linker and aptamer construct was first 
performed in silico. According to UNAFold analysis, the calculated KD value of cF9-F9aTHR 
binding in bulk conditions resulted to be in the order of magnitude of attomolar, much lower 
than the KD value obtained for F9 (see Materials and Method section) binding to the aptamer 
region alone (6.5 μM), therefore, suggesting that the immobilization of the DNA-aptamer 
constructs is occurring essentially through the cF9-F9 pairing. Using EMSA, it has been 
previously verified that both DNA-aptamer constructs were able to bind thrombin. However, 
F9-HEGL-aTHR was observed to bind more efficiently to THR compared to F9aTHR, so in 
the following experiments we decided to focus on the first construct. 
Binding affinity analysis was then performed on surface immobilized aptamers via SPR, 
following the DNA-aptamer immobilization procedure described in the previous session. A 
wide THR concentration range (0.8–200 nM) was screened with Biacore. The signal response is 
proportional to the THR concentration (Figure X); the mostly straight binding lines in the 
association phase obtained with analyte injections up to 12.5 nM show a possible mass 
transfer contribution. These curves do not display a sufficient curvature to perform kinetic 
analysis. Although an equilibrium state has not been reached for all the concentrations tested, 
we recorded the binding level at the end of the association phase. These values, plotted against 
THR concentration, were fitted with a single site interaction model. This “non-steady-state” 
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analysis implies an underestimation of the binding affinity [126,127]. Therefore, we can 
conclude from the SPR data that the KD is in the range 10–100 nM, in agreement with the value 
reported in the literature for the aptamer-THR binding (KD = 50 nM) (Figure 44). 
 
Fig. 44 SPR characterization: (a) sensograms of different THR concentrations (0.8–200 nM); and (b) 
binding affinity analysis; SPR responses at the end of the association phase are plotted against THR 
concentration and fitted (red line) to a single site interaction model ([RU] = RUmax − (1/(1 + KD/[A])) 
the black vertical line indicates the value of KD found from the RU model; the light-blue area is the 
range of possible KD values (see text). 
 
6.2 AFM MECHANICAL SENSING ON NANOSTRUCTURED ASSAYS 
The AFM nanoarray platform was built starting from cF9 DNA nanografting, on which we 
loaded via DDI the F9-HEGL-aTHR aptamer construct (Figure 45 left, top image). 
 
Fig. 45 Images of the nanopatches on the gold surface (left, scale bars 1 μm) and their topographic 
profiles (right). Black: F9-HEGL-aTHR aptamer immobilization; red: THR 12 nM incubation; and 
green: THR 1000 nM incubation. 
 
By using AFM topographic imaging, we monitored height profile changes over DNA-aptamers 
loaded by DDI on cF9 nanografted arrays (Fig. 45 left, upper patches; right, black profile) vs. 
different THR concentrations in the binding buffer (Fig. 45 left, mid and lower images; Figure 
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46 right, red and green profiles correspond to 12 nM and 1000 nM THR, respectively), due to 
the conformation change of the aptamer upon binding the ligand. In all these steps the TOEG 
SAM embedding the patches is used as a reference level to monitor topographic height 
changes. Differential height changes are shown in Figure 46a. By plotting height change vs. 
concentration, we extracted an effective dissociation constant for this system in the range 10–
100 nM, a value that is in good agreement both with literature and with the SPR results obtained 
using the same molecular construct. As one can clearly see in Figure 46, the data are affected by 
significantly large errors that could be attributed to the fact that when the ligand binds to the 
aptamer, it folds to a more compact shape. 
 
Fig. 46 (a) Comparison of binding curves obtained from the height variation measured with the AFM 
on DNA nanopatches (left) and SPR data (right) vs. THR concentration; and (b) evaluation of the 
static compressibility on DNA nanopatches at low concentrations of THR. 
 
This results in a reduced AFM differential height, since the height increase due to protein 
uptake is counterbalanced by the height decrease due to a change in binder conformation. 
Additionally, the softness of the nanopatches contributes to such large errors: the coupling of 
the aptamer to the nucleic acid linker, in fact, increases the compressibility of the entire 
nanopatch, giving more variability while measuring AFM height variation [102]. We then 
performed a so-called “compressibility analysis”: we monitored the softness of the patches, 
exposed to different THR concentrations, by imaging progressively the patches at increased 
tip load. The variation of (absolute) patch height vs. tip load for the bare DNA patches, the 
patches loaded with the aptamer constructs and then the last ones exposed to different THR 
concentrations are shown in Figure 46b. As shown in Figure 46b, while applying only 200 
pN, nanopatches can be compressed up to 40% of the height measured at minimum force 
(about 50 pN below which the AFM tip loss its contact with the surface). However, from 
such analysis we can conclude that the higher the THR concentration, the stiffer the patch 
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towards tip compression. The increase of nanopatch stiffness upon THR immobilization is 
due to the high compactness of globular proteins (as THR), much higher than for nucleic 
acids at the ionic strength used for the experiments. A stiffness change of about 30%–35% 
upon 4 nM THR binding can, in fact, be estimated from the compressibility experiments, at 
variance with the patch height that stays almost constant. 
Therefore we demonstrated the feasibility of aptamer as potential recognition molecules 
suitable for the nanoarray; the nanoarray platform has to be carefully optimized in both in the 
immobilization of the molecules by adding of a short oligo via a polyethileneglycol linker and 
by tuning aptamer surface, and in the AFM-detection strategy, due to the peculiar features of 
this oligonucleotide sequences that undergo to conformational rearrangement to bind the 
ligands. 
We obtained a value of KD in good agreement with the available literature for in bulk studies, 
demonstrating that the immobilization of aptamer via DDI on the surface preserves its 
functionality and allows successful thrombin detection. 
 
Once selected a Her2 specific aptamer a study of the nanoarray capability with respect to 
antibody/nanobody-functionalized AFM assay will be performed. However the evidences 
obtained by the different experiments presented in this work can lead to a preliminary 
consideration yet: in the AFM approach nanobodies seem to be the most promising binders 
not only for their sensitivity but mainly in terms of robustness of the assay and readout 
results. On the contrary aptamers would be preferred in some alternative surface-based 
miniaturized platforms (i.e. electrochemical impedance spectroscopy devices) characterized by 
a different readout system that fully exploits some peculiar features of this kind of molecules. 
 
7. STUDY OF THE POTENTIAL VALUE OF RELEASED ECD-
Her2 AS INDICATOR OF TUMOR PROGRESSION 
The precise quantification of circulating ECD-Her2 in blood serum and of total Her2 or 
Her2 homodimers in living cell membranes would help to classify Her2 status and to define 
the impact of shedded Her2 on prognosis and response to anti-Her2 therapies. 
However, conflicting results are correlating Her2 gene amplification, protein expression and 
cleavage of the ECD [30,46,128]; only few studies analyzed simultaneously tissue and serum 
data, to precisely understand the relationship between dimerization and ECD release at 
different level of tumor progression and in response to therapy. Clarifying whether the 
amount of shedded ECD-Her2 predicts tissue Her2 expression status, would validate ECD-
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Her2 value in serum screening as complement analysis to tissue testing both in early breast 
cancer and in metastatic disease.  
Since so far the clinical significance of circulating ECD-Her2 remains uncertain, it is a general 
opinion that this issue deserves further studies in large prospective trials, together with in vitro 
studies to elucidate fundamental aspects of the relationship between dimerization, ECD 
shedding and its prognostic/therapeutic value.  
Therefore to assess the role of shedded ECD-Her2 as tumor biomarker we studied the 
localization and quantification of Her2 levels in membranes and the correlation of this 
information with sensitive quantification of ECD-Her2 in cell medium through 
nanotechnology-based diagnostics.  
 
7.1 LOCALIZATION AND QUANTIFICATION OF Her2 ON CELL 
MEMBRANE  
We performed fluorescent labelling on SKBR3 cells (breast tumor Her2-overexpressing cell 
line), MCF7 cells (Her2-negative breast tumor cell line) and HEK293 cells (human embryonic 
kidney cell line) as negative control. We labeled fixed cell with MGR2 as primary antibody 
specific for ECD-Her2 and a secondary green fluorescent Ab to mark the target membrane 
protein; we used DAPI labeling of the nucleus for an easier identification of cells. The 
fluorescence signal has been monitored with epifluorescence inverted microscope. 
As visualized in Figure 47 by green fluorescence localized in the plasma membrane, the 
SKBR3 tumor cell line (A, B, C) shows an higher level of Her2 if compared with both the 
negative control (D) and the Her2-negative cell line (E); the overexpression in the tumor cell 
line could be connected to an oligomerization mechanism revealed by the presence of clusters 
(C – red arrow).  
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Fig. 47 Epifluorescence microscopy images of fluorescence labeled SKBR3 (A, B, C), HEK293 (D), 
and MCF7 (E) cells; ECD-Her2 has been detected by means of MGR2 as primary Ab and secondary 
α-mouse-Alexa488 Ab. Scale bars 20 μm.  
Due to resolution limit of the setup, we expect that precise localization and quantification of 
the protein of interest being hampered. In order to improve the resolution of fluorescence 
imaging, we preliminary attempted few localization and co-localization experiments with a 
commercial STED setup available in the lab of Dr. Ilaria Testa of the KTH in Stockholm. 
There we performed two series of independent experiments, labeling the ECD-Her2 (Fig. 
48A, B, C) and the ICD-Her2 (Fig. 48D, E, F), respectively, by means of an Oregon 
Green488-labeled secondary Ab targeting MGR2 in one case and an α-ICD Ab in the other. 
Results have been collected for SKBR3 and HEK293 cell lines, as in epifluorescence 
experiments. As Her2-negative cell line we used in this case a triple negative breast tumor cell 
line (MDA-MB-231).  
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Fig. 48 STED microscopy images of fluorescence labeled SKBR3 (A, D) MDA-MB-231 (B, E) and 
HEK293 (C, F); cells have been labeled to visualize ECD-Her2 (A, B, C) and ICD-Her2 (D, E, F). 
Scale bars 10 μm.  
 
Concerning ECD-Her2 we confirmed the previous results: SKBR3 cells exhibits higher 
receptor level (Fig. 48A) with respect the control cell lines (Fig. 48B, C). The increased 
resolution obtained with STED microscopy (below 50 nm) allowed also distinguishing the 
presence of Her2 clusters localized in the cytoplasmic membrane (Fig. 48A – red arrow). 
Analyzing the ICD-Her2 signal instead, we can surprisingly notice that the different cell lines 
seems to vary not much for the expression level but rather for the localization of the 
intracellular receptor domain. In SKBR3 cells the ICD-Her2, as the ECD-Her2, is visualized 
on the cytoplasmic membrane (Fig. 48D), instead on MDA-MB-231 and HEK293 cells it is 
strongly expressed into the nucleus (Fig. 48E, F). Although it is commonly known that 
tyrosine kinase receptors, such as the Her family, function as signaling initiators on the cell 
membrane, this evidence seems to be in agreement with some works present in literature 
which demonstrate that receptors or fragments of them travel from the plasma membrane to 
the nucleus by different mechanisms and may act as transcription factor in the nucleus [129]. 
Moreover it has been demonstrated that the nuclear ICD-Her2 targets several gene 
promoters to mediate gene expression. Since Her2 lacks any known structural signatures 
required for DNA association, it is likely that Her2 may associate to AT-rich DNA sequences 
and with other DNA binding nuclear factors, as histone 3 isoform [130]. Since the different 
scenario in SKBR3 cell line and the negative control ones it can be speculated that Her2 
overexpressing cells promote the molecular cascades strictly connected the membrane 
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dimerization of the receptors, the proteolytic release of ECD-Her2 and the N-terminally 
truncated Her2 increase of the tyrosine kinase activity, that activates the downstream pro-
proliferation signalling pathways rising the oncogenic potential.  
On the contrary Her2-negative cells show a genomic function of ICD-Her2 and a possible 
alternative activation of gene regulation mechanisms, responsible of the different cell 
phenotype or the different breast cancer subtype. This explanation requires additional 
measurements to be fully proved. 
 
7.2 CO-LOCALIZATION OF INTRACELLULAR DOMAIN (ICD)-Her2 AND 
ADAM10 ON SKBR3 CELL MEMBRANES 
Since the metalloprotease ADAM10 has been identified as the main ECD-Her2 sheddase, we 
studied the co-localization of the ICD-Her2 and this protease in the SKBR3 cell line (Fig. 49). 
 
Fig. 49 STED microscopy images of fluorescence labeled SKBR3; cells have been labeled to visualize 
ICD-Her2 by means of green fluorescence signal (A) and ADAM10 by means of red fluorescence 
signal (B). The super-imposition of the signals (C), and in particular the magnification of some region 
of interest (D, E, F, G) visualizes the co-localization of Her2 and ADAM10. Scale bars: (A, B, C) 10 
μm – (D, E, F, G) 1 μm. 
 
As shown in Fig. 49 by means of high resolution STED microscopy we were able to identify 
some regions in the cell membrane in which ICD-Her2 (labeled with green fluorescent dye) 
and ADAM10 (labeled with red fluorescent dye) co-localize. This first experimental evidence 
represents only a preliminary result in the global understanding of the correlation between 
Her2 overexpression status and the cleavage of its extracellular domain. Exploiting another 
super-resolution microscopy approach, called reversible saturable optical fluorescence 
transition (RESOLFT) [131], also available in the lab of Dr. Ilaria Testa, that allows an 
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extremely precise (lateral resolution between 20 and 50 nm) simultaneous localization of 
biomolecules in cells, we plan as a next step to perform the quantitative study of the co-
localized receptor-protease couples with the different levels of cell membrane receptor 
expression. 
 
7.3 CORRELATION BETWEEN ECD-Her2 LEVELS IN CELL MEDIUM AND 
Her2 TUMOR STATUS 
The relationship of Her2 overexpression status with ECD released by means of the shedding 
process has been preliminary studied in order to correlate fluorescence measurements 
described in paragraph 7.1 with the amount of ECD present in the medium of cell cultures. 
The quantitative detection of the target has been preformed by the previously described 
AFM-based nanoarray, functionalized with Trastuzumab conjugate. Fig. 50 reports the results 
related to the detection of ECD-Her2 released in the culture medium of two different cell 
lines: SKBR3, that overexpresses Her2, and HEK293, that shows a normal level of the 
receptor. Notably a height increase has been detected only when incubated with the SKBR3 
cell medium, instead no increment has been observed for the negative control. This evidence 
withstands the hypothesis that the overexpression of Her2 is directly correlated to an 
increased dimerization and shedding, and hence to a higher amount of released ECD-Her2, 
supporting the prognostic significance of this circulating biomarker. 
 
Fig. 50 Nanoarray detection of ECD-Her2 on cell culture medium. (A) Schematic representation of 
the assay. (B) Images of the nanopatches on the gold surface with relative average and standard 
deviation values of the height measured across the nanopatches at each step of the experiment 
(grafting of ssDNA; hybridization of Trastuzumab-DNA conjugate; HEK293 cell medium incubation; 
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SKBR3 cell medium incubation). 
 
8. STUDY OF Her2 STATUS IN EXOSOME-DRIVEN TUMOR 
CELL COMMUNICATION 
Quantitative fluorescence microscopy studies have demonstrated that clusters of Her2 co- 
localize with lipid rafts on Her2 overexpressing SKBR3 breast cancer cells [52,53]. Lipid rafts 
are sub-domains of the cell membrane enriched in cholesterol and glycosphingolipids, 
involved in important cellular processes, such as proteins traffic, cell polarity control and cell 
signaling alteration. Therefore rafts are considered crucial regulators of mechanism as cell 
fate, growth, adhesion and migration, all processes which are disregulated in cancer [49]. 
From the studies in ref. 52, 53, it has then been proposed that lipid rafts influence the 
association properties and the biological function of Her2. This evidence introduces two 
novel research routes towards:  
- understanding how rafts regulate Her2 dimerization and hence if/how rafts dissociation 
decreases Her2 activation. This could be useful to hypothesize an alternative therapeutic 
approach to Her2-positive breast tumor, which would involve the altering of rafts 
physiology;  
- clarifying the relationship between rafts-mediated exosomes formation and Her2 integration 
on them. Her2 dimerization in breast cancer cells seems to takes place in the specific rafts 
subfamily caveolae. Moreover it has been demonstrated that a specific caveolae protein 
Caveolin-1 is strongly expressed in exosomes secreted by tumor cells [56]. Experiments on 
co-localization of Her2 and raft-related Caveolin-1 may indicate its possible involvement in 
the biogenesis of tumor cells secreted exosomes and elucidate the significance of Her2 status 
in exosome-driven tumor cell communication as crucial mechanism in tumor spreading and 
metastasis occurrence.  
Towards this goal we used fluorescence microscopy to co-localize Her2 with other molecular 
markers of lipid rafts and specifically of caveolae; we also isolated exosomes in the medium in 
order to characterize the presence of Her2 in them through AFM-based nanoarray. 
 
 
8.1 CO-LOCALIZATION OF Her2 AND RAFTS COMPONENTS IN CELL 
MEMBRANES  
The co-localization of Her2 receptors and rafts components (i.e. GM1 ganglioside, caveolin-
1) has been performed exploiting specific markers of rafts molecular constituent, as Cholera 
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Toxin (subunit B) that binds to GM1, an Ab directed against Caveolin-1. We first labeled 
GM1 rafts components and simultaneously ECD-Her2 in Her2-positive SKBR3 cell lines and 
in Her2-negative MCF7 cell lines. The immunofluorescence results are reported in Fig. 51; we 
observed that SKBR3 cells show higher level of ECD-Her2 (red signal) with respect of the 
negative control, as already demonstrated the experiments previously discussed. Instead the 
presence of rafts GM1 (green signal) is comparable in the two cell lines, as expected. 
Interestingly in Her2 overexpressing cells receptor clusters localize on the same membrane 
regions in which GM1 is detected, supporting the hypothesis of Her2 preferential localization 
in lipid rafts. 
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Fig. 51 Immunostaining of SKBR3 and MCF7 cells; nuclei are labeled with DAPI (blue signal), GM1 
with Subunit B of Cholera toxin-FITC (green signal), ECD-Her2 with MGR2 and secondary Ab-
Texas Red (red signal). Green and red fluorescence is merged in the last column to display the co-
localization of GM1 and ECD-Her2. Scale bars 20 μm. 
 
Then we proceeded with the visualization by fluorescence of caveolae, the rafts subfamily in 
which Her2 dimerization may occur. We labeled caveolin-1 as specific caveolae marker in 
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SKBR3 and HEK293 cell lines. As shown in Fig. 52 SKBR3 exhibits a higher fluorescence 
level with respect of HEK293 of caveolin1-related signal, localized, as expected, in the 
membrane. This preliminary result is in agreement with the hypothesis that caveolae, due to 
their role in vesicles formation and transport, could be involved in the release of signaling 
molecules and the spreading in distant tissue and hence be highly expressed in tumor cells 
[55,56,57,132]. 
 
Fig. 52 Epifluorescence microscopy images of fluorescence labeled SKBR3 and HEK293 cells; 
Caveolin-1 has been detected by means of primary α-Cav1 mouse Ab and secondary α-mouse-
Alexa488 Ab. Scale bars 20 μm. 
Next step will be to perform with the STED setup the simultaneous detection of Caveolin-1 
and Her2 receptors in order to verify the co-localization of the two molecules and hence to 
speculate about rafts-mediated exosome formation and the role of Her2 
integration/dimerization on them. 
8.2 EXOSOMES SPREADING BY Her2-POSITIVE CELLS: A MULTI-
INTEGRATED APPROACH FOR THE CHARATERIZATION AND FOR 
THE CORRELATION OF Her2 STATUS IN CELL MEMBRANES AND 
RELEASED ECD-Her2 LEVELS 
Analysis and characterization of exosomes released in SKBR3 cell culture medium have been 
performed first isolating them with size-exclusion chromatography; qEV size exclusion 
columns [133] contain a resin with an approximately 75 nm pore size. Proteins and other 
contaminating molecules smaller than EVs enter the pores of the resin and are delayed in 
their passage through the column, eluting in later fractions. Depending on the pore size the 
columns have been primarily optimized for accurate nano-size vesicles, such as exosomes. 
The different collected fractions have been analyzed in protein (by means of adsorbance 
spectrophotometer measurements) and exosomes content (by means of preliminary AFM 
tapping-mode imaging in air, after fixation in 4% paraformaldehyde). No protein 
contaminants have been detected in all the fractions analyzed (the first five after the void 
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volume); instead we observed in the first two fractions different sized-nanovescicles that have 
been statistically analyzed for their dimension in terms of diameter and height (Fig. 53). 
 
Fig. 53 AFM images (topography) in air of SKBR3 cell medium derived exosomes deposited on mica 
substrate and fixed with 4% paraformaldehyde. Histograms show exosomes height and width 
distribution. 
 
The measurements in air revealed the presence of round particles of diameters ranging from 
20-90 nm and height ranging from 4-15 nm. It’s important to underline that AFM imaging in 
air can rather deform the vesicles and determine an underestimation of the height. In fact the 
absence of a liquid environment determines a “collapse” of the vesicles and an increased 
amount of adhesion points to the surface; this results in less reliable height information.  
The PFA fixation does not significantly changes the diameter and height distributions, only 
preserving a more roundish shape. The advantage coming from imaging in liquid is that the 
vesicles are less deformed and the height information therefore more reliable; however this 
kind of measurements is impaired by the movements of the nanovesicles induced by the 
interaction with the tip. Moving towards, this imaging approach would require a proper 
anchoring approach that consists in a proper immobilization of the exosomes on ad-hoc 
produced AFM-based nanoarray surfaces by means, for instance, of the exosome specific 
membrane tetraspanin CD9 [134]. This methodology ensures not only a stronger anchoring 
on the surface but also a specific recognition of exosomes, due to the presence of this 
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constitutive marker. Then the nanovesicles can be characterized in terms of membrane 
expressed protein components, as Her2 receptors to begin with, targeting them with proper 
Abs (Fig. 54).  
                  
 
At present we succeeded in the production of α-CD9 Ab-DNA conjugates and in their 
immobilization on the surface via DDI. We are optimizing the functionalized surface 
conditions in order to perform the exosomes anchoring. Once this molecular characterization 
will be obtained, in relation to different cell lines, it would be useful to distinguish specific 
subpopulations and to relate them to the originating cell (tumor versus healthy, Her2-positive 
versus Her2-negative).  
The quantification of the specific subpopulation of nanovesicles, exosomes expressing Her2 
on their surface, would help to understand their contribution to the computation of the total 
amount of ECD-Her2 (the one freely circulating and the one embedded in the vesicle 
membrane) in serum. 
Moreover a multi-integrated approach would be useful to assess the correlation between Her2 
overexpression, dimerization, ECD cleavage and exosome-driven tumor spreading, towards a 
clarification of the prognostic significance of Her2-related circulating biomarkers.  
The results of the experiments discussed above can be merged in order to correlate 
information coming from advanced microscopies (membrane proteins localization), 
nanotechnology-based diagnostic tools (detection of protein and vesicle biomarkers) and 
novel super resolution fluorescence microscopies (quantification and co-localization of 
different biomarkers). An example of the multi-integrated experimental design is described in 
Fig. 55. 
Fig. 54 Schematic representation of the experimental 
approach for exosomes immobilization on gold surface and 
their characterization by means of Abs specific for different 
membrane receptors. 
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Fig. 55 Schematic representation of the multi-integrated approach to study the correlation between 
Her2 overexpression, dimerization, ECD cleavage and exosome-driven tumor spreading. 
 
Towards this direction we already got results related to SKBR3 cells: the Her2 overexpression 
detected in cell membrane is consistent with the presence of ECD fragment and exosomes 
released in the medium. The possibility to separate the nanovesicles fraction from the protein 
content released in the medium will be a crucial tool for the comprehension of how these two 
different biomarkers contribute to ECD-Her2 significance in diagnosis. A quantitative 
consideration about the relationship of Her2 status and circulating biomarkers spreading will 
be performed with the analysis of cell lines with a different Her2 expression signature (i.e. 
SKBR3 versus MCF7 and HEK293) or with different tumor progression or 
primary/metastatic nature (i.e. SKBR3 versus MDA-MB-453).  
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 DISCUSSION 
 
The use of miniaturized devices in liquid biopsy for cancer biomarker detection and therapy 
monitoring will ultimately improve the outcome of tumor early diagnosis and treatment. Here 
we trial a nanoarray based on AFM nanolithography, DNA-directed immobilization of 
protein binders and topographic readout for the detection of cancer-relevant biomarkers 
circulating in the bloodstream. We focused on the detection of ECD-Her2, optimizing the 
choice of binders to increase detection sensitivity, even in multiplexing with uPA, to move 
towards a biomolecular footprint of the disease. We demonstrated that this simple assay has 
the required sensitivity to be operated in the clinics, allows detection in small volumes of 
complex matrices, enabling continuous non-invasive therapy monitoring from single blood 
droplets (few microliters). Moreover, at variance with ELISA, it requires a single binder for 
each biomarker and is label-free, avoiding false results connected to fluorescence interference 
susceptibility, overall tremendously reducing diagnostics costs while maintaining high 
biorecognition specificity and fast readout. A simplified, automatized, cantilever-based 
readout machine can in fact be conceived for antigen quantification purposes. 
In particular we demonstrated that nanoarrays employing panning-selected camelid 
nanobodies can detect ECD-Her2 up to less than 200 pM, which corresponds to the cut-off 
value of 15 ng/mL currently used in clinics to discriminate between healthy and pathological 
status. We showed that the high affinity of nanobodies can be fully exploited by tuning 
binders surface density: at variance with classical antibodies, for which steric hindrance can 
promote anti-cooperativity of adjacent binders, higher probe densities are allowed for smaller 
binders and indeed help improving the overall sensitivity for target identification. We expect 
that the optimization of the linker length and the in silico engineering for boosting the affinity 
for cognate antigen will enable improving substantially the use of nanobodies as capture 
molecules and further drop the detection limit.  
Our platforms are ready to perform biomarkers detection in real blood serum samples 
(exploiting our collaboration with the Department of Medical and Biological Sciences - 
University of Udine and with the Department of Experimental Oncology and Molecular 
Medicine - Istituto Nazionale Tumori): once proved non–invasive monitoring in single blood 
droplets, our method might then have a crucial impact on therapeutic drug monitoring, 
profiling simultaneously multiple circulating biomarkers, accounting for time evolution of 
cancer genome and consequent resistance occurrence to drugs treatment. All this features 
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heighten the significance of our nanoarray as an attractive platform for personalized cancer 
diagnostic applications. 
Moreover, the same nanoarray can serve as a platform for epitope binning. This, combined 
with fluorescent assays in living cell membranes for co-localization of different receptors, will 
help understanding the specific functions habilitated by selective binding, paving the way to 
modular design of synthetic binders. 
Since the presence of controversial results concerning the classification of Her2 status and its 
correlation with circulating ECD-Her2 impairs a clear definition of the impact of shedded 
Her2 on prognosis and response to anti-Her2 therapies, we performed studies in vitro to 
assess Her2 biology and evaluate ECD-Her2 prognostic value through the correlation 
between overexpression/dimerization/ECD-Her2 released in normal and cancer cell lines. 
Also we developed nanotechnology-based platforms to detect Her2 in exosomes, to address 
their role in cell-cell communication and ultimately in metastasis occurrence. Moving towards 
this goal we preliminarily evaluated with standard and super-resolution microscopies Her2 
quantification and co-localization with other molecular markers of lipid rafts in tumor and 
healthy cells; then we set up a multi-integrated approach to correlate shedded ECD-Her2 and 
selection/characterization of the Her2 presence in cell-released exosomes, detected through 
nanotechnology-based devices, with the fluorescence outputs. This part of the research is still 
ongoing. 
Finally, in a different benchmarking context, that is THR detection, we proved that another 
class of binders, short nucleic acid aptamers, can be easily and efficiently integrated in the 
nanoarray for multiplexing analysis. First, we demonstrated in bulk that, by linking a short 
oligo via a polyethileneglycol linker to an aptamer designed and optimized for thrombin 
recognition, the binding affinity was preserved. Then, by immobilizing the DNA-aptamer 
construct on a SPR chips via DNA-directed immobilization and performing binding affinity 
measurements via SPR, we obtained a value of KD in good agreement with the available 
literature for in bulk studies, demonstrating that the aptamer functionality was retained upon 
surface immobilization. Successful thrombin detection was achieved by tuning aptamer 
surface density on the active area to low values in order to allow aptamers conformational 
rearrangement necessary to bind the ligands. The measured binding affinity curves 
overlapped with SPR data impressively well. In particular, DNA nanoarrays also allowed for 
an estimation of the binding affinity which resulted in good agreement with SPR data. Here, 
the change of conformation of aptamer upon THR binding towards a more compact 
structure worked reducing the expected height variation due to immobilization of THR on 
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the device. Although still detectable, the error associated to the measurements makes this 
device less reliable than SPR chips to measure binding affinity. However, mechanical 
compressibility measurements performed on the nanopatches helped to validate the result. 
The height change measurements on the nanoarrays, moreover, can be combined with the 
monitoring of roughness variations on the patch and outside it to infer the occurrence of 
specific binding only on the patch, and exclude the presence of aspecific binding outside it, 
even without the use of (expensive) sandwich schemes.  
We put forward the idea to complement our data with AFM-based force spectroscopy 
measurements to investigate the variation of the mechanical properties of the DNA-aptamer 
conjugate structures upon ligand binding. This additional strategy might be particularly 
profitable given the peculiar properties of aptamers, which undergo a global conformational 
change upon binding. Once validated aptamers as powerful binders suitable for high sensitive 
protein detection, Her2 specific aptamer will be selected to study the nanoarray capability 
with this innovative binder category and to evaluate their performance in terms of sensitivity 
and selectivity with respect to antibody/nanobody-functionalized AFM platform. 
 
Although the DNA-based nanoarray used throughout this work has been obtained from a 
serial fabrication process (i.e. nanografting one DNA patch at the time), mass production of 
multiple-spot nanoarrays can be envisaged by using parallel writing, supramolecular strategies 
and simplified, low-cost, easy to use detection systems. Parallel writing can be obtained by 
means of a set of parallel cantilever or by in situ parallel synthesis of DNA strands on 
the chip layer-by-layer (as used by all of the major DNA sequencing companies as Affymetrix, 
Illumina and Agilent to produce arrays with short and uneven oligo length, [135] or by the 
employment of photo-active molecules [136] immobilized on a micro-/nano-array prepared 
by state-of-the-art lithography techniques, as X-ray lithography, e-beam lithography, EUV 
lithography, focused ion-beam lithography.  For master replication, supramolecular strategies 
as supramolecular nanostamping (SuNS), a technique used for replicate DNA masters based 
on the hybridization (or enzymatic in situ synthesis) [137,138] of oligos of DNA onto a 
master DNA array [139] could be employed, to obtain a sort of in situ synthesis easily scalable 
to any number of spots. For detection, a simplified topographic readout machine with parallel 
cantilevers, or the implementation of the multiplexing device into a microfluidic setup with 
electrical output can be envisaged.  
At the end, in comparison with nanografting, the proposed scalable strategies would reduce 
the precision of molecular conformation and density control, a price paid in favor of a faster 
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and high throughput nanoassay. 
Our work finds its deep meaning in the framework of what is called translational research for 
personalized medicine: we aim at studying biological phenomena as Her2 protein expression 
and interactions with other molecules in membranes of tumor-related cell lines, to define new 
biomarkers for early disease detection and therapy monitoring, and ultimately to translate 
them into novel targets for “personalized” anti-cancer treatments, to treat this multi-faceted 
disease by more optimally matching drugs and individuals. 
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 MATERIALS AND METHODS 
 
DNA 
ssDNA sequences (SH-cF9: SH-(CH2)6-5’-CTTCACGATTGCCACTTTCCAC-3', F9: NH2-
(CH2)6-5'-GTGGAAAGTGGCAATCGTGAAG-3', SH-cF5: SH-(CH2)6-5’-
CTTATCGCTTTATGACCGGACC-3', F5: NH2-(CH2)6-5'-
GGTCCGGTCATAAAGCGATAA-3') were from Biomers GmbH Ulm, Germany. 
Antibodies and Nanobodies 
Monoclonal mouse antibodies MGR2 and MGR3 [104,105] were produced at Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan. These Abs have been tested in IHC, Immuno 
Precipitation (CoIP) and Immuno Blot assays [104,105]. 
Commercial monoclonal human antibodies Trastuzumab and Pertuzumab were from 
Genentech. 
Commercial monoclonal α-uPA and α-CD9 antibodies was from MyBioSource. 
Single-domain antibodies (VHH) were isolated and produced at the University of Nova 
Gorica (Slovenia) as described previously using a naïve nanobody library [116], a differential 
panning approach on whole cells and the cytoplasmic expression of the nanobodies in the 
presence of sulfhydryl oxidase [117]. 
Aptamers 
Centre of Excellence for Biosensors, Ajdovščina (Slovenia), provided the selection and 
affinity characterization of the DNA-aptamer constructs, first carried out in silico using the 
web service UNAFold, developed by Zucker and his coworkers [140]. The designed aptamer 
constructs were further tested in bulk conditions for their functionality, testing the binding 
affinity for human thrombin (THR) in a qualitative electrophoretic mobility shift assay 
(EMSA). Two different aptamer constructs were prepared: the one in which the F9 sequence 
is directly extending from the aptamer sequence (5’-
GGTTGGTGTGGTTGGGTGGAAAGTGGCAATCGTGAAG-3’), named F9aTHR and 
with hexaethyleneglycol (HEGL) linker in between, (5’-GGTTGGTGTGGTTGG-HEGL-
GTGGAAAGTGGCAATCGTGAAG-3’), named F9-HEGL-aTHR. 
Proteins and Standardized serum 
Recombinant human ECD-Her2 and uPA were from ACRO Biosystems. 
Standardized human serum was from Biseko® (Biotest). 
 
 
 86
CONJUGATES PRODUCTION 
Antibodies 
The conjugation of Abs MGR2, MGR3, Trastuzumab, Pertuzumab and α-CD9 Ab with the 
ssDNA sequence F9 and of α-uPA Ab with F5 was performed by means of click chemistry 
reaction exploiting the commercial 3-step Protein-Oligo Conjugation Kit SoluLink. 
- Protein Modification: Antibodies at a concentration of 2.5-4.0 mg/mL were buffer 
exchanged into Modification Buffer (100 mM phosphate, 150 mM NaCl, pH 8.0) usingZeba 
Desalt Spin Columns (Pierce Chemical) before adding 10-20 mole equivalents of 
HyNic/mole antibody. The reaction was carried out at room temperature for 1.5 hours and 
successively the HyNic-modified antibody was desalted into conjugation buffer (100 mM 
phosphate, 150 mM NaCl, pH 6.0).  
- Oligonucleotide Modification: The oligonucleotide was desalted into nuclease free water 
using a 5K MWCO VivaSpin diafiltration apparatus and OD/μL concentration at 260 nm 
was adjusted to 0.2-0.5 OD/ μL. A volume containing 20 equivalents S-4FB was added to the 
oligonucleotide solution and incubated at room temperature for 2 hours. The 4FB-modified 
oligonucleotide was equilibrated into conjugation buffer (100 mM phosphate, 150 mM NaCl, 
pH 6.0).  
- Protein-Oligo Conjugation: Volumes of the antibody and oligonucleotide are mixed adding 
1/10 volume 10X TurboLink Catalyst Buffer was added to the conjugation solution and the 
reaction was carried out at room temperature for 2 hours; the amount of the two components 
used in this step is strictly related to the concentration and the Molar Substitution Ratio 
(MSR) of both HyNic-modified protein and 4FB-modified oligonucleotide obtained in the 
previous steps. 
The conjugation reaction is visualized spectrophotometrically by determining the absorbance 
at A354 due to the formation of the chromophoric conjugate bond. The reaction solution 
was exchanged in PBS using Zeba columns.  
Nanobody 
The conjugation of nanobody EM1 with the ssDNA sequence F9 was performed by means 
of a maleimide reaction: the nanobody, containing a free cysteine at its C-term, was diluted to 
a concentration of 100 μM in Hepes 10 mM pH 7.4 buffer and kept reduced by the addition 
of TCEP in 10-fold molar excess for 20 minutes at room temperature. F9-maleimide was 
dissolved in TE buffer (Tris 10mM, EDTA 1mM) pH 8.0 and then added to the nanobody 
with a molar ratio ssDNA: protein of 10:1 (250:25 μM:μM). After 2 hours at room 
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temperature the modified nanobody was separated from reactants and reaction byproducts 
using a G-25 Illustra Microspin Columns (GE Healthcare Life Science). 
 
SURFACE PLASMON RESONANCE 
• Antibodies and nanobody 
Biacore T100 and Biacore 2000 Surface Plasmon Resonance (SPR) instrument were used at a 
constant temperature of 25°C. Two experimental designs were set up. 
In the first one the recombinant ECD-Her2 protein (diluited in 10 mM Na acetate, pH 4.5) 
was immobilized over the Biacore CM5 gold chip surface (the dextran matrix immobilized on 
the gold surface is decorated with many COOH groups) via amine coupling reaction, 
according to the manufactures’ instructions. A binding level of ~1300 RU was reached. HBS-
EP+ buffer was flowed (5 μL/min) as running buffer over the surface. Binding affinity tests 
of the Abs MGR2 and MGR3 and the VHH EM1 and their conjugate MGR2-F9, MGR3-F9 
and EM1-F9 were performed injecting different concentrations of analytes in running buffer 
at a flow rate of 30 µl/min for 3 minutes (association phase) and afterwards flushing with 
running buffer for 5 minutes (dissociation phase). For the regeneration of the surface 1 min 
pulses of a Gly-HCl pH 2.0 solution were used, followed by a stabilization time of 15 min 
[141].  
In the second experimental design a bionitilated cF9 sequence (cF9-biotine, 2 μM in PBS 
buffer) was immobilized over the Biacore SA gold chip surface. A continuous flow (5 
μL/min) of PBS buffer (running buffer) was maintained during all the experiments. The 
immobilization through streptavidin-biotin binding was stopped after reaching a binding level 
of ~1200 RU, corresponding to an amount of ssDNA on the surface that ensure an efficient 
attachment of the molecules in the following steps of the experiment; then the surface was 
rinsed with two 1 min pulses of 50 mM NaOH solution, in order to remove unbound cF9-
biotine [142]. The hybridization was carried out by incubation with the conjugates at 100 μM 
in TE buffer with 1M NaCl until reaching a binding level of ~ 1200 RU; binding affinity of 
the ECD-Her2 was evaluated injecting two different concentrations of the protein in running 
buffer at a flow rate of 30 µL/min for 3 min (association phase) and afterwards flushing with 
running buffer for 10 min (dissociation phase). Since the dissociation phase allows a complete 
detachment of the protein no regeneration procedure is required. 
Binding affinity parameters were determined using the BIAevaluation 3.1 software: SPR 
responses at the end of the association phase are plotted against analyte (A) concentration 
and fitted to a single site interaction mode ([RU] = RUmax – (1/(1 + KD/[A]))) to 
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extrapolate the dissociation constant KD. This parameter describes the binding affinity and is 
the ratio koff/kon. 
• Aptamers 
To test aptamer affinity on surfaces, a Biacore X100 Surface Plasmon Resonance (GE 
Healthcare) instrument was used at a constant temperature of 25 °C. A continuous flow (5 
μL/min) of PBS buffer (running buffer) was maintained during all the experiments. First, a 
biotinilated cF9 sequence (cF9-biotin, 2 μM in PBS buffer) was immobilized over the Biacore 
SA gold chip surface. The immobilization through streptavidin-biotin binding was stopped 
after reaching a binding level of ~1200 RU, corresponding to an amount of ssDNA on the 
surface that ensure an efficient attachment of the molecules in the following steps of the 
experiment; then the surface was rinsed with two 1 min pulses of 50 mM NaOH solution, in 
order to remove unbound cF9-biotin [142]. The hybridization was carried out by incubation 
with F9-HEGL-aTHR at 30 μM in TE buffer with 1 M NaCl until reaching a binding level of 
~500 RU, to form an active layer suitable to detect a binding signal also with the lowest 
concentrations of analyte. The immobilization procedure was followed by a flow of running 
buffer for 2 h in order to remove aptamers non-specifically bound to the surface and to 
stabilize the baseline. After this procedure the signal remained constant without any baseline 
drifting. Binding affinity tests were performed injecting different dilutions of thrombin (0, 
0.2, 0.8, 3.1, 12.5, 50, and 200 nM) in running buffer at a flow rate of 30 μL/min for 3 min 
(association phase) and afterwards flushing with running buffer for 5 min (dissociation 
phase). For the regeneration of the surface 1 min pulses of a 50 mM NaOH solution were 
used, followed by a stabilization time of 5 min [143]. Binding affinity parameters were 
calculated using the BIAevaluation 3.1 software. 
 
AFM MEASUREMENTS 
• Ab/Nb-functionalized nanoarray 
Tip-assisted AFM-based nanolithography technique used to fabricate DNA nanoarrays 
and all high-resolution topographic measurements have been performed using an XE-100 
(Park-Systems) with a custom liquid cell at room temperature. First, a biorepellent Self-
Assembled Monolayer (SAM) of top oligo-ethylene glycol-terminated alkylthiols (TOEG6: 
HS-(CH2)11-(OCH2CH2)6-OH, Sigma Aldrich) was prepared on ultraflat stripped gold 
surfaces following a modified version of the Ulman procedure [144]. A gold sample was 
soaked in a 300 μM solution of TOEG6 in ethanol for about 24 hours. Then, it was rinsed 
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with distilled water and ethanol, dried with a gentle stream of nitrogen, and finally glued 
inside the AFM liquid cell. 
Multiple Nanografting Assembled Monolayers of thiol modified ssDNA SH-cF9 (SH 
modification at 5’ end) were prepared by serial AFM-based nanografting inside the 
TOEG6 SAM [74,145,146]: an AFM tip with sufficient rigidity (MicroMasch NSC 19/no 
Al, spring constant 0.6 nN nm-1) was operated at high load (set point/force 100 nN) on 
areas of 1 μm x 1 μm or 2 μm x 2 μm in order to locally displace the TOEG6 SAMs and 
to facilitate the exchange with the thiolated ssDNA biomolecules (5 μM in TE buffer 1 M 
NaCl) present in the liquid cell.  
Antibody/nanobody conjugate immobilization was performed via DNA Directed 
Immobilization (DDI) [86,107], incubating the ssDNA SAM with Abs/VHH-F9 at 100 
nM in TE buffer with 1M NaCl. ECD-Her2 binding was promoted through the 
incubation of the antibody/nanobody nanopatches with a solution containing 
recombinant protein at different concentrations in PBS buffer (binding curves 
determination and multiplexing measure) or in Biseko (detection in standardized human 
serum) with the same incubation time. 
Topographic height variations of the nanopatches at each step of the experiment were 
measured with AFM in gentle contact mode in liquid using a softer AFM tip 
(MicroMasch CSC 38/no Al, spring constant 0.03 nN nm-1), in buffer solution (TE 
buffer, Tris 10 mM, EDTA 1 mM). In order to minimize perturbation applied force 
during measurement was the minimum stable value (0.1 nN). We already proved that at 
these conditions nanostructures can be imaged and their height referred to the SAMs 
carpet (Δh) can be measured [146]. Results of the AFM topography analysis were 
expressed as mean±standard deviation (SD) obtained from measurements performed on 
at least four independent patches (n ≥ 4). 
The fabrication parameters of the nanografting process were systematically tuned and 
consequentially the density of ssDNA molecules adsorbed in the nanopatch modified 
[1,8,34]. In particular it was possible to control the nanoscale DNA surface by modifying 
the number of scanning lines during nanografting over the area, a parameter described by 
the S/A ratio (where S is the scanned area and A is the area of the final patch) [113]. 
Regeneration conditions were tested to remove ECD-Her2 (50 nM) from MGR2-
functionalized nanoarray: Glycine-HCL pH 1.5–3, NaOH pH 10, 5 M NaCl solutions.  
 
 
 90
• Exosomes analysis 
Exosomes were adsorbed to freshly cleaved mica sheets, fixed with 4% 
paraformaldehyde, and analysed by MFP-3D Stand Alone AFM (Asylum Research) and 
Solver Pro (NT-MDT) Atomic Force Microscopes. For imaging in air conditions, we 
worked in dynamic mode conditions using silicon probes (spring costant 0.5-4 N/m, 
radius of curvature <10nm, Mikromasch). For imaging in liquid conditions, we worked in 
dynamic mode conditions using silicon nitride probes (spring costant 0.05-0.39 N/m, 
radius of curvature <10nm, Olympus).  Topographic height and phase images were 
acquired at 128x128, 256x256 and 512x512 pixels with a scan rate typically of 1-2 Hz in 
air and 0.5-1 Hz in liquid. In order to extract mean height and width of exosomes, we 
used image processing and particle analysis macros of Igor Pro and Gwyddion softwares. 
 
• Aptamer nanoarray 
A tip-assisted AFM-based nanolithography technique has been used to fabricate DNA 
nanoarrays with high surface density (1–2 × 1013 molecules/cm2): using Si cantilevers 
(NSC36B Mikromasch, spring constant: 0.6 N/m) multiple nanografting assembled 
monolayers (NAM) of thiol-modified single-stranded DNA (ssDNA), named cF9, were 
prepared by serial AFM-based nanografting inside a self-assembled monolayer (SAM) of a 
top oligo ethylene glycol terminated alkanethiol, TOEG ((1-mercaptoundec-11-
yl)hexa(ethyleneglycol), HS-(CH2)11-(OCH2CH2)6-OH from Sigma Aldrich) on ultraflat 
gold surfaces following standard protocols reported earlier. The DNA patches were 
obtained promoting the replacement of the TOEG molecules with the oligonucleotides 
by the AFM tip scanning an area of 1 μm × 1 μm or less at high force (about 100 nN) in 
the presence of a solution of thiolated ssDNA sequences (5 μM in TE buffer 1 M NaCl) 
at a scan rate of 2 Hz. Several patches (6–8 for each experiment, to guarantee good 
statistics) of cF9 ssDNA were produced.  
Aptamer immobilization was performed via DDI, incubating the ssDNA SAM with 1:1 
mix of F9-HEGL-aTHR and F9 at 2 μM in TE buffer with 1 M NaCl in order to avoid 
steric hindrance by reducing the aptamer surface density, hence, preserving the activity.  
Aptamer-thrombin binding was promoted through the incubation of aptamer 
nanopatches for one hour with a solution (volume of about 100 μL) containing thrombin 
at different concentrations (THR buffer: 20 mM Tris pH 7.4, 140 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 1 mM CaCl2); topographic height variations over the NAMs were measured 
with AFM in gentle contact with standard silicon cantilevers (CSC38 Mikromasch, spring 
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constant: 0.06 N/m) at a 1 Hz scan rate, applying a force of 0.1 nN to detect and quantify 
binding affinity. 
 
FLUORESCENCE IMAGING 
• Nanoarray 
Fluorescence measurements were performed both on direct and indirect “sandwich” 
configuration. Monoclonal IgG antibodies specific for ECD-Her2 (MGR2, 
Transtuzumab and Pertuzumab) were directly immobilized via DDI on the surface, 
incubating the ssDNA nanopatches with the immunoconjugate at 100 nM in TE buffer 
1M NaCl. ECD-Her2 binding to immobilized antibodies was obtained incubating 
nanopatches with a solution containing ECD-Her2 at 100 pM (nanoarray validation) or 
10 nM (“epitope mapping” studies).  
With respect to direct measurements, EM1-GFP fusion construct (1 μM) was incubated 
for 1 hour over the surface; indirect measurements were performed using a second Ab 
specific for ECD-Her2 at the saturating concentration of 500 nM and then the secondary 
fluorescent α-muose_Alexa488 Ab (Termofisher Scientific) diluted 1:500 in PBS buffer 
and incubated over the surface for 30 minutes. After repeated washing steps with PBS 
buffer, the gold sample was mounted on a glass coverslip with Vectashield H-1400 
mounting (Vector). 
Fluorescent images were acquired on an inverted epifluorescence microscope (Nikon 
Eclipse TiU) using 20x (NA=0.45) and 40x (NA=0.70) air objectives and a dichroic filter 
for FITC (Nikon, Exc: 465-495 nm DM: 505 nm Em: 515-555 nm). 1600x1200 pixels 
images were collected using a color digital camera and controller (Nikon DS-Fi2 and 
Digital Sight DS-L2) at acquisition times ranging from 1 to 10 s. 
 
Fig. 56 Schematic representation of the two different fluorescence assay: in the first one (A) 
different combinations of two Ab/Nb are exploited to built the “sandwich” of ECD-Her2 
binding. The fluorescence signal is obtained with a secondary fluorescence α-mouse Ab. In the 
other configuration (B) EM1 conjugated with GFP is exploited as second Ab of the “sandwich”. 
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• Cells 
Cells were fixed in 4% paraformaldehyde (20 minutes at room temperature); to avoid 
aspecific binding cells were incubated for 30 minutes at room temperature with blocking 
buffer (PBS in the presence of 5% FBS) and 0.1% TritonX-100 (if permeabilization is 
required).  
Her2 receptor (ECD and ICD), caveolin-1 and ADAM10 protease were labeled with 
saturating concentration of specific unlabeled primary antibodies for 60 minutes at room 
temperature in PBS. The dye-conjugated secondary Ab was then added. In order to label 
lipid rafts cells were incubated in the presence FITC-labeled subunit B of cholera toxin 
for 60 minutes at room temperature. Nuclei were labeled with DAPI (4',6-diamidino-2-
phenylindole - 1.5 μg/mL) by means of incubation of 10 minutes. After each incubation 
step unbound antibodies were removed by washing twice with PBS. 
Fluorescent images were acquired on an inverted epifluorescence microscope (Nikon 
Eclipse TiU) using 20x (NA=0.45) and 60x (NA=0.70) air objectives and a dichroic filter 
FITC (Nikon, Exc: 465-495 nm DM: 505 nm Em: 515-555 nm), TxRed (Nikon, Exc: 
540-580 nm DM: 595 nm Em: 600-660 nm) and UV-2A (Nikon, Exc: 330-380 nm DM: 
400 nm Em: 420-up nm). 1024x1024 pixels images were collected using a color digital 
camera and controller (ORCA Flash4.0 e software HCImage 4.3.1.30 - Hamamatsu) at 
acquisition times ranging from 20 ms to 10 s. 
Stimulated Emission Depletion (STED) microscopy is a confocal super-resolution 
imaging technique. STED super-resolution is obtained by overlaying an excitation laser 
and a depletion laser to subtract fluorescence in specific regions of the sample while 
leaving a center focal spot active to emit fluorescence. For STED experiments KK114-, 
Alexa488-, Oregon Green488-conjugted secondary Abs were used; STED images were 
acquired with commercial STED instruments (Leica SP8 3X STED and Leica SP5 NIR-
STED), using a white light laser tuned to 470 nm to excite the Alexa488 and Oregon 
Green488 fluorescence and 640 nm to excite the KK114. For STED images, Alexa488 
and Oregon Green488 were used with the 592 nm depletion laser set to 95 % power with 
a time gating range of 1.5–6.0 ns, and KK114 was used with the 775 nm depletion laser 
set to 95 % power with a time gating range of 1.2–6.0 ns. 
CELL CULTURE 
SKBR3, MCF7 and HEK293 cell lines were obtained from the American Type Culture 
Collection (ATCC) and, according to their specifications, were routinely grown in DEMEM 
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supplemented with 10% FBS and penicillin/streptomycin. Cells were maintained at 37 ̊C in a 
humidified atmosphere of 95% air and 5% CO2. For immunofluorescence experiments cells 
were grown on glass coverslips. 
 
EXOSOMES EXTRACTION 
In order to isolate exosomes from culture medium, cells were grown in FBS free DEMEM 
supplement with 1% BSA and penicillin/streptomycin for 24-48 hours at 37 ̊C in a 
humidified atmosphere of 95% air and 5% CO2. Cell medium was then picked up and 
centrifuged first at 300 g and then at 2000 g for 10 minutes to eliminate cells and debris. 
For exosomes isolation the size-exclusion qEV columns [133], composed by a resin with an 
approximately 75 nm pore, were used. After the wash of the column with PBS buffer, the 
medium sample was loaded on the top; more buffer was added to let the sample entered the 
column. Immediately the first 3.5 mL were collected as void volume; after the void volume 
the vesicle fraction of 1 mL was collected. 
 
ELISA ASSAY 
The indirect ELISA assay was performed first by coating the antigen ECD-Her2 to PVC 
microtiter plate. The protein was diluted to a final concentration of 100 μg/mL in carbonate 
buffer (100 mM, pH 9.6) and 50 μL were used to coat the microplate wells overnight at 4 °C. 
Then the coating solution was removed and the plate washed three times with PBS. The 
coated wells were blocked with 1% BSA in PBS (blocking buffer) for 2 hours at room 
temperature. The plate was washed twice in PBS and serial dilutions (from 100 pM to 1 μM) 
of primary antibody were added. The plate was washed three times with PBS after 4 hours 
incubation at 4 °C and finally the Horse Radish Peroxidase (HRP)-conjugated secondary 
antibody (Sigma) diluted 1:2000 in blocking buffer was added. After the incubation (1 hour at 
4 °C) binding detection was assessed by adding the substrate 3,3’,5,5’-tetramethylbenzidine 
(TMB, Pierce). The reaction was stopped with a solution of HCl 1 M after 15 min of 
incubation at room temperature and optical density was read at 450 nm. 
 
STATISTICAL ANALYSIS 
• The Limit of Blank (LoB) is the highest measured test result likely to be observed 
(typically at 95% certainty) for a sample containing no analyte. Values above LoB are 
not consistent with the absence of analyte; hence LoB frequently replaces the 
analytical sensitivity of a method. It is calculated as follow: 
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LoB = Meanblank + 1.645*(SDblank) 
• The Confidence Level is the percentage of all possible samples that can be expected 
to include the true population parameter. For example, supposing all possible samples 
were selected from the same population and a confidence interval was computed for 
each sample, a 95% (or 0.95) confidence level implies that 95% of the confidence 
intervals would include the true population parameter. It is calculated estimating the 
population mean, the standard deviation and the multiplier (t-value), using a t-table in 
which the degree of freedom is based on the sample size, n. A normal random 
variable X is transformed into a z-score via the following equation: 
z = (X - mean) / SD 
The z-score is then converted into a confidence level using a z-score table. 
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 APPENDIX 
Other AFM-based nanoarrays applications: Mismatch detection in DNA 
monolayers 3 
Controlled nanoscale DNA patterning and DNA-based nanoarray can offer a broad set of 
possible applications that allow, by means of DNA hybridization, to detect specific disease 
biomarkers. So far different methodologies have been developed in order to increase the 
selectivity and the sensitivity of DNA/RNA expression profiling, oligonucleotides 
mismatches detection, microRNA (miRNA) detection. 
In this direction we present here two platforms based on different sensing strategies, to detect 
mismatched and/or perfectly matched complementary DNA strands hybridization into 
ssDNA oligonucleotide monolayers. 
 
Most current technologies for genotyping and sequencing are based on DNA hybridization, 
exploiting the high grade of selectivity due to the unique properties of DNA base pairing. 
Although the understanding of the behavior of nucleic acids on a solid surface has made huge 
progress from the seminal work of Southern [147] due to the rapid development of DNA 
microarray and DNA microarray-based techniques [82,148], there are still open questions and 
bottlenecks limiting the selectivity and the sensitivity of devices that are based on the 
hybridization of DNA [149]. One example is the detection of single nucleotide polymorphism 
(SNP) [150]. Single-base variations in a DNA/RNA sequence afflict 1 out of 1000 base pairs 
in the genome causing small differences in individuals belonging to the same species. This can 
lead to diseases [151,152,153] or drastically affect the response to pharmacological treatments 
[154]. SNPs are particularly relevant for applications in the field of pharmacogenomics and 
population genetics, as a diagnostic tool towards a personalized approach to diseases [155]. 
However, state-of-the-art devices still are not fully able to identify a single-base mismatch nor 
to unequivocally distinguish fully and partially matching sequences during hybridization 
[156,157].  
The most common strategies for mismatch detection can be divided in three different 
categories: hybridization-based detection, detection based on thermal denaturation and 
protein-mediated detection [150]. For each strategy, different readout systems and 
experimental designs have been reported, which include fluorescence [158], surface plasmon 
                                                   
3  "Mismatch detection in DNA monolayers by Atomic Force Microscopy and Electrochemical Impedance 
Spectroscopy" M. D. Nkoua Ngavouka, P. Capaldo, E. Ambrosetti, G. Scoles, L. Casalis, P. Parisse. Beilstein J 
Nanotechnol. 2016; 7: 220–227. 
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resonance [159,160], electrochemical [161,162], atomic force microscopy [163,164], 
colorimetric assays [165], Raman spectroscopy [166]. However, all these state-of-the-art 
technologies are limited in multiplexing implementation, mutation discrimination and/or 
sample throughput. Therefore the field is still open for an optimization of strategies to 
overcome the current limitations [167].  
We present here two platforms, which are based on different sensing strategies, to detect 
mismatched and/or perfectly matched hybridization of complementary DNA strands into 
ssDNA oligonucleotide monolayers. The first platform exploits atomic force microscopy-
based nanolithography (nanografting) to create ssDNA nanoarrays on gold surfaces and then 
AFM topography measurements to monitor the variation of the height of the nanostructures 
after loading the complementary/mismatched strands in the liquid cell. In the last years we 
optimized this nanomechanical approach, which is based in the different rigidity of ss- and 
dsDNA [81,102,109], enabling the ultrasensitive detection of biomarkers [101]. The second 
strategy exploits the change in capacitance during the hybridization process, measured at the 
interface between a ssDNA-functionalized gold electrode and the solution in an 
electrochemical cell. In a previous work we demonstrated the ability to follow the 
hybridization of perfectly matched sequences in real time through electrochemical impedance 
spectroscopy (EIS) measurements on extended ssDNA self-assembled monolayers (SAMs) 
[168]. Here we successfully tested EIS for the detection of mismatched sequences. From the 
analysis of hybridization kinetics we distinguished the presence of single or multiple 
mismatches and their relative position.  
Both nanoarrays and EIS devices hold the premises for parallelization, multiplexing and low-
volume analysis, making them amenable for point-of-care diagnostics of SNPs. Moreover a 
comparative analysis between the two techniques allows for a deep understanding of 
hybridization processes in the presence of single and multiple mismatches.  
 
Results and Discussion  
Atomic force microscopy-based assay  
In Figure 1 we report a schematic representation of the AFM- based assay. We immobilize by 
means of nanografting on a gold surface two ssDNA sequences, differing by one base (re- 
ported as a red mark), and carefully measure the height of the DNA nanostructures with 
respect to the surrounding biorepellent self-assembled monolayer, this last serving as a 
constant reference for the height measurements (hssDNA, Figure A1a). Then we hybridize 
with a sequence that is perfectly complementary to one of the two sequences. We expect the 
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perfect matched (PM) sequence and the one-base mismatched (MM) sequence hybridization 
to produce a similar increase in height, which follows the change in the nanomechanical 
properties from ssDNA to dsDNA configuration (hdsDNA, Figure A1b). We then perform a 
thermal treatment to selectively de-hybridize only the MM sequences, as we can measure 
from the different height response of the two grafted ssDNA structures (hafter treatment, 
Figure A1c). Since the non-perfectly matching sequence will have a reduced melting 
temperature with respect to the perfectly matched (PM) sequence (Tm(MM) < Tm(PM)), its 
de-hybridization will be favored upon annealing to a temperature (Tann) close or slightly 
higher than the melting temperature of the perfect matched sequence (Tm(MM) < Tm(PM) 
≤ Tann). We have used our AFM-based nanomechanical approach to distinguish single 
mismatched DNA base pairs of single nucleotide polymorphisms (SNPs), in particular a T–G 
mismatch.  
 
Figure A1: Schematics of the atomic force microscopy-based assay. We graft two sets of ssDNA 
nanostructures, whose sequences differ by one single base, highlighted by a red dot (panel a, b,c). By 
means of careful AFM topographic measurements, we record the height varia- tion over the ssDNA 
nanostructures, (hssDNA, panel a) upon hybridization with a strand fully matching only the left 
grafted strand (hdsDNA panel b), upon thermal treatment, (hafter treatment, panel c), evidencing the 
different de-hybridization behaviour of perfectly matched sequences vs mismatched sequences. 
  
In particular, we chose to immobilize on the surface two 25 bases-long ssDNA sequences, 
HS-SNP-C and HS-SNP-T (see Table 1) differing from one cytosine vs one thymine. We 
produced by nanografting patches of each of the two ssDNA sequences into 1 μm2 areas in 
the biorepellent TOEG6 SAM, using the same grafting parameters (Figure A2a).  
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Table 1: List of the sequences used for the AFM and EIS experiments. The position of the 
mismatches is typeset in bold.  
 
After grafting, the sample was incubated with the sequence SNP-coC fully matching one 
strand and matching the second one but for one base, originating a T/G polymorphism. In 
Figure A2b we report the AFM topographic image after incubation with SNP-coC targets for 
1 h. The height variation (Δh = h − hssDNA) after the hybridization step is very similar for 
the two different sequences (Figure A2d), evidencing the impossibility to clearly distinguish 
the presence of the mismatched base only by means of height measurements. We therefore 
designed a melting experiment: we kept the sample in TE buffer, pH 9, for 1 h at 60 °C, a 
temperature slightly higher than the melting temperature of the PM sequence (TmPM = 57 
°C, TmMM = 53 °C). In Figure A2c we report the AFM topographic image after the thermal 
treatment and in Figure A2d the relative height changes. We can observe a sensible height 
decrease in the HS-SNP-T probe only, matching almost completely the initial ssDNA value. 
This is the sign of a complete de-hybridization of the mismatched sequence, whereas the 
perfect match probe is only slightly perturbed by this thermal treatment.  
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Figure A2: Schematic view and AFM topographic images of HS-SNP-C and HS-SNP-T nanografted 
patches (a) before and (b) after incubation with SNP-C for 1 h and (c) thermal treatment. (d) 
Histogram of the height variation with respect to the ssDNA patches (Δh = h − hssDNA) after the 
hybridization with SNP-C-Co sequence and after the thermal treatment (1 h at 60 °C).  
These successful preliminary experiments demonstrate that our system has the ability to 
detect mismatches after precise annealing steps, as the ones used in current melting-based 
SNPs assays [169,170]. The novelty of our assay resides in the possibility of reducing the 
dimensions of the spots (below 1 μm2) and to work multiplexing in small volumes. The use 
of locked nucleic acids or enzyme-based strategies [167] might improve sensitivity further 
possibly circumventing the annealing step.  
 
Electrochemical impedance spectroscopy- based assay  
Despite the high sensitivity, the AFM assay does not allow, at the moment, for a real-time 
investigation of binding events. In order to overcome such limitations, we tested in parallel 
another device developed in our laboratory [168], based on electrochemical impedance 
spectroscopy (EIS) [171]. The device exploits the capacitive effects at the interface between 
an electrode and an electrolytic solution. When a potential is applied to the gold electrode the 
free ions in solution will rearrange close to the surface creating the so-called double layer 
capacitance (CDL) [172,173]. In presence of a molecular layer between the solution and the 
electrode, an additional capacitance in series has to be taken in account. In our case, similarly 
to the AFM experiments, we functionalized the electrode with a low density ssDNA 
monolayer that serves as a probe for hybridization studies. In Figure A3 we report a scheme 
of the device as a series of two capacitances, one due to the charged DNA strands, CssDNA 
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and the other (CDL) to the pure ionic solution [174]. The measurements of the total 
differential capacitance will be dominated by the smaller capacitance and, since CssDNA 
(densities of about 10 μF/cm2) < CDL (densities of about 40 μF/cm2) [168], will give us a 
reasonable estimation of the CssDNA. In the approximation of parallel plate capacitance we 
can write CssDNA as ε·ε0(A/d), where A is the area of the electrode, d the thickness of the 
ssDNA layer, and ε0 and ε are the dielectric constant of vacuum and ssDNA layer, 
respectively. When we insert a complementary strand in the electrochemical cell, the 
molecular recognition between the two strands will cause a change in the capacitance at the 
interface, due to a combination of height changes, displacement of water molecules upon 
binding of new strands, and rearrangement of charge density, bringing to a new value for the 
capacitance, CdsDNA [175]. Our device can follow the variation of capacitance in real time, 
allowing for the study of the kinetic of hybridization. Indeed, the eventual presence of a 
mismatch should change the kinetic of the binding, as already reported by pioneering work of 
Georgiadis’s group [78,176]. Therefore, following in real time the variation of the capacitance 
we expect to distinguish the presence of mismatched sequences.  
We functionalized the electrode with the HS-SNP-T probe and measured the capacitance at 
the electrode (red dots in Figure A3).  
 
 
Figure A3: Schematic representation of the electrode/electrolyte interface. The first layer in contact 
with the gold electrode is the ssDNA self-assembled monolayer, modelled as a capacitance CssDNA. 
Then we have the ions present in solution that arrange in response to the gold and DNA charges 
forming the so-called double layer capacitance CDL, in series with CssDNA. When hybridization 
occurs, the binding of the complementary strand will produce a change in capacitance due to height 
changes, substitution of water molecules in the biological layer, and changes in the electrical charge 
density. The capacitance, extracted from the impedance measured in our electrochemical setup, is 
plotted versus time for the ssDNA-functionalized electrode (red curve) and for the mismatched 
(green) and perfectly matching (blue) complementary sequences.  
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The value of CssDNA is shown to be constant over an hour of continuous measurements, as 
already demonstrated by Ianeselli et al. [168]. After addition of the perfectly matching 
sequence SNP-coT (blue squares) in the electrochemical cell, we observed a fast decrease of 
the capacitance, followed by a subsequent slow decay that reaches a plateau at a value of 
capacitance 36% less than the initial value, as a sign of the occurred hybridization. When we 
insert on the regenerated electrode with the HS-SNP-T probe the mismatched sequence 
SNP-coC (green triangles) we observe a slower decay of the capacitance tending to a plateau 
much closer to the initial CssDNA value than the perfectly matched one (21% variation), 
confirming a different kinetic behavior and a less efficient hybridization. Our results are in 
good agreement with previous reports of Georgiadis based on SPR measurements [176]. We 
can observe here that the EIS measurements allow for distinguishing the mismatched and 
perfectly matched sequences by observing a different kinetic behavior and a different 
capacitance plateau, whereas AFM was not able to directly detect a height difference. Indeed, 
the changes of capacitance at the functionalized electrode are the results of a combination of 
changes of height in the molecular case and rearrangement of charge density. The distortions 
on the DNA structure due to the mismatched bases can modify the charge distribution inside 
the molecular layer [177], causing a change in the capacitance that is readable in the EIS 
measurement, even if does not significantly affect the height of the layer after the 
hybridization.  
We further tested our device exposing a 44 bases ssDNA (HS_ssDNA_44) probe to five 
different sequences: a perfect match (cDNA_44_PM), a double mismatch (cDNA_44_2MM), 
a triple mismatch (cDNA_44_3MM), and two 22 bases sequences complementary to the 
bottom half (cDNA_44_DOWN) and top half (cDNA_44_UP) part of the ssDNA_44 
sequence, respectively.  
In Figure A4a we report the study of the kinetics of DNA hybridization in the presence of 2 
MM (green triangles) and 3 MM (black markers) mismatches compared with the PM (blue 
squares) sequence. We can clearly distinguish the behavior of the three differently matching 
sequences. As expected we measured a slower kinetics and a lower plateau value going from 
the PM (36% variation) to 2 MM (17% variation) and finally to 3 MM (10% variation).  
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Figure A4: Differential capacitance measurements of the kinetics of DNA hybridization in presence 
of multiple mismatches (a) and in presence of partially complementary sequences (b). The red signal 
represents the differential capacitance of a low-density 44 bases ssDNA SAM functionalized WE 
measured in 100 mM KCl. (a) In blue we report the hybridization with the fully matching sequence, in 
green the hybridization with a sequence with 2 MMs, and in black the hybridization with a sequence 
with 3 MM. (b) In blue we report the hybridization with the fully matching sequence, in orange the 
hybridization with a 22mer sequence complementary with the upper part (far from the gold surface) 
of the target and in purple the hybridization with a 22mer sequence complementary with the lower 
part (close to the gold surface) of the target.  
Analogously, we observe in Figure A4b the evolution of the differential capacitance in 
presence of two 22 bases-long sequences complementary to the bottom half 
(cDNA_44_DOWN) and top half (cDNA_44_UP) part of the ssDNA_44 sequence, 
respectively. The curves follow more or less the same trend: an initial fast decay and then a 
slow decay to an asymptotic value representative of the efficiency of the hybridization. The 
kinetics and the asymptotic value are, respectively, slower and lower for the two half 
sequences with respect to the PM. Notably, the kinetics and efficiency of hybridization is 
much lower for the down matching sequence than for the up matching sequence. The 44 
bases probe brush can in fact hinder the hybridization of the bottom part, while the upper 
part is made more available for the target sequence. Noteworthy, we observe a sensible 
variation between up and down hybridization in the presence of as low as 20 nM target 
concentration. The increase in sensitivity with respect to previous results reported by 
Georgiadis group [176] can be attributed to the applied electric field during the EIS real time 
hybridization measurements. Such electric field can indeed favor the hybridization process, as 
already reported by [178], accelerating the kinetics and improving the efficiency of the 
hybridization.  
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Conclusion  
We proposed here two different sensing strategies based on the use of ssDNA monolayers 
tethered to gold substrates, for the detection of mismatches in DNA oligonucleotides. Both 
the strategies are label-free and are sensitive enough to detect point mutations. In Table 2 we 
report a comparison between the performance of our two approaches (nano-mechanical and 
electro-chemical) and current label-free surface-based biosensing strategies, according to 
recent literature. As we can see from the table, SPR strategies seem to be the most promising 
in terms of limit of detection. However, in these devices the surface area is larger, limiting 
multiplexing and small volume operations [159,160].  
By contrast, the nano-mechanical approach on DNA nanoarrays although hampered by the 
time consuming processes of annealing and AFM height measurements (in line with 
benchmark of AFM-based assays reported in literature [156,163,164]), allows for a 
straightforward multiplexing. Ultimate sensitivity has been demonstrated for these arrays (100 
pM, [179]), making them overall amenable to less invasive diagnostic analysis with a sensible 
reduction of the volume of the analyte till single cell [101].  
Finally, our electrochemical measurements combine high sensitivity with real-time analysis, 
allowing for an accurate study of the kinetics and of the efficiency of the hybridization in 
mismatched targets. In our case, we were able to clearly distinguish the presence of single, or 
multiple mismatches and also the position with respect to the gold surface of the missing 
base-pairs. Due to the relatively simple geometry, the device could be easily further 
miniaturized and integrated in multiplexed arrays through microfluidic systems, allowing for 
point-of-care diagnostics. Our results demonstrated that nano-mechanical and EIS strategies 
are state of the art for the detection of SNP, con- firming the relevance of immobilized DNA 
on solid supports in life science studies, including single cell RNA characterization, gene 
expression profile and genetic variability. Moreover, the complementarity of the two 
techniques (one more sensitive to the morphological and mechanical changes of the DNA 
layer, the other more sensitive to its charge density) let us conclude that the structural 
deformations related to a single mismatch have a strong influence on the charge distribution 
only, leaving the molecular structure not significantly affected.  
 
Materials and Methods 
Fabrication and measurement processes of AFM-based assays  
Gold-coated substrates were immersed in 300 μM of top oligo(ethylene glycol)-terminated 
alkylthiols (TOEG6: HS–(CH2)11–(OCH2CH2)6–OH) ethanol solutions, overnight, to allow 
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for the adsorption and assembly of a full monolayer with bio-repellent characteristics [112]. 
The samples were then removed from the solution, rinsed with ethanol and water to remove 
loosely bound molecules and placed in a customised liquid cell for the AFM experiments.  
All AFM experiments were carried out on a XE-100 Park Instruments with a customised 
liquid cell. Si cantilevers (NSC36B Mikromasch, spring constant: 0.6 N/m) were used for the 
nanografting experiments. Briefly, the AFM tip is scanned at high load (approx. 100 nN) over 
the TOEG6 SAM, operating in a buffer solution (10 mM Tris-HCl, 1 mM EDTA, (hereafter 
TE), 1 M NaCl, pH 7.1) containing 5 μM thiolated ssDNA oligonucleotides. The applied load 
is sufficient to displace the TOEG6 molecules from the gold surface, which are subsequently 
locally substituted by the thiolated ssDNA molecules, creating ssDNA patches embedded in 
the surrounding TOEG6 carpet. Exchanging the buffer and the thiolated ssDNA probes, it is 
possible to sequentially immobilize different sequences on the same substrate. The 
parameters for nanografting have been properly chosen to obtain a surface density of probes 
optimal for the detection of target hybridization, following previous works of our group 
[81,102,109]. After the immobilization the ssDNA patches are measured through AFM 
topographic imaging in soft contact with standard silicon cantilevers (CSC38 Mikromasch, 
spring constant: 0.06 N/m) at 1 Hz scan rate, applying a force of 0.1 nN. Hybridization was 
monitored after the addition of the required target solutions (1 μM target in TE buffer 1 M 
NaCl) into the AFM liquid cell for 1 h. All DNA sequences used in the present work are 
listed in Table 1.  
 
Fabrication and measurement processes for EIS-based assay  
Detailed fabrication processes and layout of the electrochemical impedance spectroscopy 
experiments have been reported by Ianeselli and co-workers [168]. Briefly, the setup consists 
of a glass slide with lithographically fabricated working (WE) and counter (CE) gold 
electrodes. The two electrodes are covered with insulating resist leaving exposed to the 
solution only the active part, to avoid spurious effects. To confine the drop of solution and to 
carefully position the reference electrode (a classical millimetre-sized Ag/AgCl pellet 
electrode) we placed around the electrodes a silicone circular cell (6 mm in diameter, 4 mm in 
height). The WE and CE electrodes were functionalized with thiolated ssDNA molecules 
using a well-established procedure for DNA SAMs on gold [79,81]. Initially the electrodes 
were wetted for 10 min with a drop of a high-ionic- strength buffer, TE 1 M NaCl, 
containing 1 μM thiolated ssDNA. In this way a low-density ssDNA SAM (about 2 × 1012 to 
3 × 1012 molecules/cm2) was obtained [79]. After DNA- functionalization the devices were 
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rinsed with the buffer solution used for the measurements, 100 mM KCl, and the capacitance 
at the electrode/electrolyte interface was measured. In the hybridization step the cell is filled 
with a drop of the same hybridizing buffer solution, 100 mM KCl, containing the 
complementary or partially complementary DNA strand at different concentrations.  
The electrochemical current Irms is monitored between WE and CE with a Heka PG340 
USB potentiostat upon application of a 10 mV AC voltage at 100, 200, 250 and 400 Hz. In 
this regime of frequencies the total impedance is dominated by the capacitance at the 
electrode/electrolyte interface, allowing for the ex traction of the differential capacitance 
simply from a linear fit of Irms. The functionalized electrodes can be regenerated after the 
hybridization process by means of a thermal treatment in TE buffer (pH 9) for 1 h in oven at 
a temperature 10 °C higher than the melting temperature of the used DNA sequence. The 
differential capacitance after the regeneration treatment maintains its original value within the 
error bars. 
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